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Cytochrome P450s (CYPs) are a superfamily of monooxygenases catalyzing the 
metabolism of various endogenous and exogenous compounds. CYP2J2 is highly 
expressed in the cardiovascular system and catalyzes the metabolism of arachidonic acid 
to give four vasoactive epoxyeicosatrienoic acids (EETs). Similar to the endogenous 
cannabinoid system, CYP2J2 is also expressed in the gastrointestinal tract, liver, kidney, 
and the brain. Therefore, we investigated the ability of CYP2J2 to metabolize 
anandamide (AEA), an endogenous cannabinoid, and JWH-018, a synthetic cannabinoid, 
thereby contributing to the regulation of the ECS. 
 We determined that purified CYP2J2 metabolizes AEA to give the 5,6-, 8,9-, 
11,12-, and 14,15-epoxyeicosatrienoic acid-ethanolamides (EET-EAs) and 20-
hydroxyeicosatrienoic acid-ethanolamide (HETE-EA) and characterized the metabolism 
in detail. Since AEA plays a role in energy balance, we investigated AEA metabolism by 
rat liver microsomes from rats bred to be susceptible or resistant to diet-induced obesity 
and determined that both diet and obesity have significant effects on AEA metabolism. 
Approaches for increasing the stability of the EET-EAs may aid in understanding their 
biological actions in vivo. Therefore, we tested several inhibitors of soluble epoxide 
hydrolase (sEH), the enzyme primarily responsible for EET hydrolysis, as inhibitors of 




efficacious and that new inhibitors specific for the EET-EAs’ epoxide hydrolases need to 
be developed. 
Finally, we determined that JWH-018 is a substrate for CYP2J2 and characterized 
its metabolism in detail. JWH-018 is a drug of abuse that causes several adverse 
cardiovascular side effects, but relatively little is known about the metabolism or the 
pharmacology of this compound. Utilizing an animal model, we determined that JWH-
018 causes a significant increase in blood pressure that appears to be only partially 
mediated by activation of the cannabinoid 1 receptor. Additional studies are required to 
fully understand the involvement of CYP2J2 in the ECS; however, because CYP2J2 
regulates the metabolic fates of at least two ligands for the ECS, it is possible that 








Cytochrome P450s. Cytochrome P450s (P450s or CYPs) are members of a class 
of heme proteins that catalyze oxidation-reduction reactions. CYPs are distinct from all 
other members of this group because when the heme iron is reduced, it can bind to carbon 
monoxide and form a Soret peak with the wavelength for its maximum absorbance near 
450, hence the name P450 (pigment absorbing at 450 nm). These P450s form their own 
superfamily of hemeprotein monooxygenases that are responsible for the metabolism of 
many exogenous and endogenous compounds. Individual CYPs are named based on their 
relative sequence homologies. P450s with at least 40% sequence homology are grouped 
into families and that family is given an Arabic numeral (1, 2, 3, etc.). CYPs with a 
sequence homology of 55% or greater are assigned to the same subfamily and are 
differentiated using a letter of the alphabet (A, B, C, etc.). Each member of the subfamily 
is then given an Arabic numeral corresponding to its sequence in discovery, i.e. CYP1A2. 
This name also corresponds to the gene, which is written in italics. 
P450s can either activate or inactivate compounds and the ultimate outcome of 
P450-catalyzed metabolism is usually to make a compound more water soluble to aid 
with excretion from the body. CYPs have the ability to insert one oxygen atom from 
molecular oxygen (O2) into a substrate while concurrently reducing the other oxygen 




mechanism, P450 enzymes are known to catalyze hydroxylations, epoxidations, N-
oxidations, dehalogenations, N-, S-, and O-dealkylations, sulfoxidations, and numerous  
other types of reactions (Ortiz de Montellano, 1995). 
When a substrate binds in a substrate binding site of the active site of the P450, it 
induces a conformation change of the active site that may cause a water molecule to be 
displaced from the distal axial position of the heme iron (Meunier et al., 2004). This may 
then cause the heme iron to change from a low spin state to a high spin state which favors 
the transfer of an electron from nicotinamide adenine dinucleotide phosphate (NADPH) 
to the heme iron of the P450 by cytochrome P450 reductase (Poulos et al., 1987; Sligar et 
al., 1979). The electron transfer reduces the ferric heme iron of the resting P450 to the 
ferrous state allowing molecular oxygen to covalently bind to the distal axial position of 
the heme iron forming a ferrous P450-dioxygen complex (Ortiz de Montellano, 1995). 
The environment surrounding the oxygen atom allows the oxygen to be activated to a 
greater extent than in many other heme proteins which thus facilitates the transfer of a 
second electron from either cytochrome P450 reductase or cytochrome b5 to form a 
peroxoiron(III) complex (Ortiz de Montellano, 1995). At rates too fast to be observed, the 
negatively charged peroxo group is rapidly protonated, the oxygen-oxygen bond is 
cleaved, the distal oxygen atom is incorporated into a water molecule, and a reactive iron-
oxo complex is formed (Ortiz de Montellano, 1995). The oxygen atom is transferred from 
this iron-oxo species to the bound substrate followed by the dissociation of the product 
(Ortiz de Montellano, 1995). After the product is released from the active site, the CYP 
returns to its original state with a water molecule occupying a position close to the distal 




CYPs have been identified in all domains of life, including animals, plants, fungi, 
and bacteria (Nelson, 2009). There are over 13,000 known P450s, and the genes for 57 
have been identified in humans by the Human Genome Project (Nelson, 2009). CYPs are 
expressed in almost all tissues in the body, but the liver is the tissue with the highest 
expression levels of P450s. As a result of their high expression and critical roles on drug 
metabolism, P450s expressed in the liver have been well studied. P450s are also 
expressed in almost all extrahepatic tissues, including, but not limited to, the lungs, 
gastrointestinal tract, kidney, heart, and nasal tissue (Chaudhary et al., 2009; Pavek and 
Dvorak, 2008; Wu et al., 1996). CYP2J2 is one P450 that is mostly expressed in 
extrahepatic tissues. CYP2J2 is one of the main P450s responsible for the 
biotransformation of arachidonic acid (AA) to its four regioisomeric epoxyeicosatrienoic 
acids (5,6-, 8,9-, 11,12-, and 14,15-EET). Because of the importance of the biological 
actions of the EETs in the body, it is important to study CYP2J2 catalyzed reactions and 
how other substrates interact with fatty acid metabolism. 
Cytochrome P450 2J2. Although this P450 was originally cloned from a cDNA 
library of the human liver, cytochrome P50 2J2 (CYP2J2) levels are relatively low in the 
liver compared to other P450s. On the other hand, CYP2J2 is highly expressed in the 
heart and in the cardiovascular system (Delozier et al., 2007; Wu et al., 1996). CYP2J2 is 
expressed in large and small coronary arteries, coronary artery smooth muscle cells, the 
aorta, vascular endothelial cells, and varicose veins (Bertrand-Thiebault et al., 2004; 
Delozier et al., 2007; Node et al., 1999; Wu et al., 1996). In addition to vascular tissues, 
CYP2J2 is expressed in the lung, kidney, liver, skeletal muscles, gastrointestinal tract, 




et al., 2011; Enayetallah et al., 2004; Jiang et al., 2005; Wu et al., 1996; Zeldin et al., 
1997; Zeldin et al., 1996). 
 Substrates. In addition to arachidonic acid, CYP2J2 metabolizes several other 
polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA), 
docosahexaenoic acid (DHA), and linoleic acid (LA). CYP2J2 metabolizes EPA to 
17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and DHA to 19,20-
epoxydocosapentaenoic acid (19,20-EDP)(Arnold et al., 2010). It was reported that at 
nanomolar concentrations, 17,18-EEQ and 19,20-EDP act as antiarrhythmic agents by 
inhibiting the Ca
2+
-induced increased rate of spontaneous beating cardiomyocytes from 
neonatal rats (Arnold et al., 2010). CYP2J2 metabolizes linoleic acid (LA) to 9,10- and 
12,13-epoxyoctadecenoic acids (EOAs) (Moran et al., 2000). These LA metabolites can 
reach millimolar concentrations in the serum of patients with significant burns (Kosaka et 
al., 1994). The presence of these compounds is associated with increased mortality in 
severely burned patients, as well as in patients suffering from systemic shock or adult 
respiratory distress syndrome (Kosaka et al., 1994; Moran et al., 2000; Ozawa et al., 
1986). Moran and coworkers reported that linoleic acid and its monoepoxides induce 
mitochondrial dysfunction in a concentration dependent manner without causing 
oxidative stress prior to cell death (Moran et al., 2000). Our lab has investigated the 
ability of recombinant CYP2J2 to metabolize two other fatty acids, linolenic and dihomo-
γ-linoleic acid, but no metabolism was observed (unpublished data). 
In addition to PUFAs, CYP2J2 is known to catalyze the metabolism of the non-
sedating antihistamines terfenadine, ebastine, and astemizole. CYP2J2 catalyzes the 




al., 2006), the carboxylation of hydroxyebastine (Liu et al., 2006), and the O-
demethylation of astemizole (Matsumoto et al., 2002). Several CYP3A4 substrates have 
been screened to see if they could serve as CYP2J2 substrates because of the similarities 
of the structures of the active sites of the two proteins. However, due to the relatively 
narrow channel available for the entry of potential CYP2J2 substrates into the active site, 
only seven new CYP2J2 substrates were identified from a total of 139 CYP3A4 
substrates assayed (Lee et al., 2012). Lee and coworkers determined that the CYP3A4 
substrates albendazole, amiodarone, cyclosporine A, danazol, mesoridazine, tamoxifen, 
and thioridazine were also substrates for CYP2J2 (Lee et al., 2012). More recently, Wu et 
al. (2013) reported the that CYP2J2 is a major contributor to the hydroxylation of 
albendazole and fenbendazole (Wu et al., 2013). Data suggest that CYP2J2 is also 
involved in the ω- and ω-1 hydroxylation of eperisone (Yoo et al., 2009). Similar to 
various other P450s, CYP2J2 is known to have its in vivo activity altered by a variety of 
inhibitors, inducers, and mutations. 
Inhibitors. Several inhibitors of CYP2J2 activity have been investigated, but the 
inhibition appears to be substrate specific. N-Methylsulphonyl-6-(2-proparglyloxy-
phenyl)hexanamide (MS-PPOH), 2-(2-propynyloxy)-benzenehexanoic acid (PPOH), and 
17-.octadecynoic acid (17-ODA) are routinely used to inhibit CYP2J2 epoxygenase 
activity in studies of arachidonic acid metabolism (Jiang et al., 2005; Ke et al., 2007; 
Zhao et al., 2012).  Ren and others have studied additional compounds for their ability to 
inhibit CYP2J2 activity and three were identified (Lee et al., 2012; Ren et al., 2013). Ren 
et al. (2013) determined that flunarizine is a competitive inhibitor of astemizole O-




during the same study as a mixed-type inhibitor of astemizole O-demethylation with a Ki 
of 0.19 µM (Ren et al., 2013). Lee and coworkers reported that danazol competitively 
inhibited both the hydroxylation of terfenadine with an IC50 of 77 nM and astemizole O-
demethylation with a Ki of 20 nM (Lee et al., 2012). Because the development of a 
selective CYP2J2 inhibitor would be of great benefit in understanding the role of CYP2J2 
in cardiovascular homeostasis, Lafite and others synthesized a number of CYP2J2 
inhibitors structurally related to terfenadine and ebastine (Lafite et al., 2007; Lafite et al., 
2006). Three compounds were determined to be selective for CYP2J2 inhibition. 
Compound 4 was identified as a competitive inhibitor of CYP2J2 which exhibited a Ki 
value of 160 nM (Lafite et al., 2007; Lafite et al., 2006). The other two inhibitors, 
compounds 5 and 13, where classified as mechanism-based inactivators with kinact/Ki 




 (Lafite et al., 2007; Lafite et al., 2006). 
Inducers. Contrary to the major P450 epoxygenases in the CYP2C family that are 
induced by nifedifpine, cortisol, and statins (Bauersachs et al., 2002; Fisslthaler et al., 
2000; Fisslthaler et al., 2003), none of those compounds induce CYP2J2 mRNA or 
protein expression (Spiecker and Liao, 2005). However, EPA has been shown to induce 
CYP2J2 mRNA expression in a time- and dose-dependent manner (Wang et al., 2009). 
Moreover, EPA increased the cellular concentration of 11,12-EET significantly (Wang et 
al., 2009). These increases in CYP2J2 mRNA and 11,12-EET levels were significantly 
inhibited by the peroxisome proliferator-activated receptor γ (PPARγ) antagonist, 
GW9662, suggesting that PPARγ activity can alter CYP2J2 expression levels (Wang et 
al., 2009). One group reported that cocaine upregulated the expression of a P450 in the 




Although it was reported as CYP2J2, mice do not express CYP2J2, but they do express 
several of its homologues, including CYP2J5, CYP2J6, CYP2J8, CYP2J9, CYP2J11 and 
CYP2J12 that may have cross-reacted with the CYP2J2 antibody (Nelson, 2009). 
Polymorphisms. The CYP2J2 gene is located on chromosome 1 and is 
approximately 40.3 kb in length with nine exons and eight introns (Ma et al., 1998). A 
considerable number of single nucleotide polymorphisms (SNPs) have been identified for 
CYP2J2, some of which are nonsynonymous and cause a protein coding change. King 
and others reported that the CYP2J2 variants D342N (CYP2J2*5) and P351L exhibit 
catalytic activity similar to that of the wild-type protein (CYP2J2*1) for AA and LA 
metabolism and astemizole O-demethylation and ebastine hydroxylation, respectively 
(King et al., 2002; Lee et al., 2005). Whereas the I192N (CYP2J2*4) variant exhibits 
decreased metabolism for AA only, mutants T143A (CYP2J2*2), R158C (CYP2J2*3), 
and N404Y (CYP2J2*6) exhibit decreased activity for the metabolism of both AA and 
LA when compared to wild-type (King et al., 2002). Out of 93 Korean subjects, 1.6% 
expressed the G312R mutant which, compared to wild-type, showed minimal 
functionality for the catalysis of astemizole O-demethylation (Lee et al., 2005). The most 
functionally relevant mutant discovered so far in humans is thought to be CYP2J2*7. 
This mutant contains a SNP in the proximal promoter of the CYP2J2 gene where a 
guanidine is substituted for a thymidine at the -50 position. Carriers of this mutation 
experience a 50% loss in promotor activity because the Sp1 transcription factor binding 
site is absent (Spiecker et al., 2004). In a study to determine the effect of the CYP2J2*7 
variant, it was determined that subjects  expressing this mutation had a significantly 




disease (Spiecker et al., 2004).  The overall importance and actual mechanisms by which 
these polymorphisms contribute to cardiovascular diseases such as hypertension and 
coronary artery disease remain to be elucidated; however, there is some evidence that the 
effects may be dependent on ethnicity (Dreisbach et al., 2005; Fava et al., 2010; Lee et 
al., 2007; Polonikov et al., 2008). 
Arachidonic Acid Metabolism. AA metabolism in the heart occurs in the 
myocardial, endothelial, and vascular smooth muscle cells. Most of the AA in the heart is 
esterfied to the sn-2 position of phosphotidylethanolamine or phosphotidylcholine. 
Activation of phospholipases of the A2 family (PLA2s) determines the rate of eicosanoid 
production because they catalyze the release of the arachidonic acid from cellular 
phospholipids (Jenkins et al., 2009). The three phospholipases that catalyze AA release 
from cellular membranes are iPLA2β, iPLA2γ, and cPLA2α. Although all three of these 
phospholipases are calcium independent, iPLA2β is catalytically inactive when associated 
with camodulin, which provides some calcium mediated control (Wolf and Gross, 1996). 
Once released from cellular phospholipids, the free AA can then be oxidized by 
cyclooxygenases, lipoxygenases, and cytochrome P450 enzymes (Figure 1.1). 
Metabolism of AA by Cylcooxygenase (COX). Prostaglandin synthase (PGS) or 
COX utilizes its cyclooxygenase activity to catalyze the addition of two oxygen atoms to 
AA to form prostaglandin G2 (PGG2). The enzyme’s peroxidase activity subsequently 
converts PGG2 to the prostanoid series-2 precursor prostaglandin H2 (PGH2). In the heart, 
PGH2 is converted to prostaglandin E2, prostaglandin F2α, and  prostaglandin I2 by their 
respective synthases (Jenkins et al., 2009). Both COX-1 and COX-2 are found in the 






Figure 1.1. Arachidonic acid oxidation in the body. COX, cyclooxygenase; EET, 
epoxyeicosatrienoic acid; HETE, hydroxyeicosatrienoic acid; HpETE, 
hydroperoxyeicosatraenoic acid; P450, cytochrome P450; PG, prostaglandin; THETA, 




normal cardiovascular function since it is constitutively expressed (Zidar et al., 2007). 
Conversely, COX-2 is induced in several pathological states and depending on the extent 
of induction, the pathophysiological condition, and ability of specific cells to form the 
cardioprotective prostaglandins, PGE2 and PGI2, determines if COX-2 mediated 
inflammation is beneficial or detrimental (Pitt et al., 1983; Shinmura et al., 2000; Wong 
et al., 1998; Wu, 1998). 
Metabolism of AA by Lipoxygenase (LOX). Lipoxygenases produce hydroperoxy-
eicosatraenoic acids (HpETEs) by catalyzing the oxidation of olefin linkages in AA. 
Studies using rat hearts and cultured cardiomyocytes have shown that 12-LOX is 
responsible for most of the lipoxygenase activity, while 15-LOX only catalyzes a small 
portion of reactions (Breitbart et al., 1996). HpETEs are subsequently reduced to 
hydroxyeicosatetraenoic acids (HETEs) by several different enzymes, including 
phospholipid hydroperoxide glutathione peroxidase and cystolic glutathione peroxidase 
(Bhatia et al., 2012; Jakobsson et al., 1997; Sutherland et al., 2001). Although the 
importance of LOX and its metabolites in cardiac function and homeostasis remain 
relatively unknown, this pathway is believed to be involved in insulin sensitivity and in 
the development of cardiac fibrosis and hypertrophy (Dransfeld et al., 2002; Wen et al., 
2003). 
Cytochrome P450-catalyzed Metabolism of AA. Cytochrome P450s metabolize 
AA to epoxyeicosatrienoic acids (EETs) and HETEs. Due to the relative promiscuity of 
many of the CYPs, several P450 families are known to metabolize arachidonic acid. 
Members of the CYP4A, 4B, and 4F families are known to serve as ω-hydrolases and are 




(Chaudhary et al., 2009; Powell et al., 1998; Roman, 2002). In vascular smooth muscle 
(VSM) cells, 20-HETE is a potent vasoconstrictor that prevents the depolarization of 




 (KCa) channels (Roman et al., 2000).The 
vasoconstriction mediated by 20-HETE normally occurs in small arteries and arterioles 
no larger than 100 µm in diameter (Roman, 2002). Structural analogs of 20-HETE such 
as 5-, 15-, and 19-HETE block its actions in certain vascular beds (Alonso-Galicia et al., 
1999). Although the exact mechanism that 20-HETE utilizes to block KCa channels has 
not yet been determined, studies using animal models have reported activation of protein 
kinase C (PKC), mitogen-activated protein (MAP) kinase signal transduction, 
extracellular signal-related kinase (ERK), and tyrosine kinase by 20-HETE, depending on 
the cell type (Lange et al., 1997; Sun et al., 2002). Activation of MAP kinases is the 
mechanism used by 20-HETE to induce VSM cell proliferation (Muthalif et al., 2001). In 
addition, 20-HETE is thought to play an influential role in the autoregulation of blood 
flow, as well as myogenic responses to changes in vascular pressure, and it is thought to 
act as an oxygen sensor in the microcirculation in certain tissues (Frisbee et al., 2001; 
Gebremedhin et al., 2000; Harder et al., 1996; Imig et al., 1999; Imig et al., 1994). 
Enzymes from P450 families 1A, 2B, 2C, 2E, 2J, 3A, and 4A can catalyze the 
formation of arachidonic acid epoxide metabolites (Daikh et al., 1994; Laethem et al., 
1994; Mitra et al., 2011; Rifkind et al., 1995; Roman, 2002; Scarborough et al., 1999; 
Wang et al., 1996). There are four potential epoxides that can be formed as a result of 
P450-mediated AA metabolism; however, the efficiency and metabolite profile by which 
the various CYP isoforms produce these epoxides are different. The 2C and 2J families 




the CYP2C isoforms are mostly responsible for EET synthesis; however, CYP2J2 is 
believed to play a major role in the metabolism of AA in the cardiovascular system due to 
its much higher expression levels relative to CYP2C8 and CYP2C9 in the heart (CYP2J2 
> CYP2C8) and in the vascular tissues (CYP2C9 > CYP2J2 > CYP2C8) (Askari et al., 
2013; Delozier et al., 2007; Spiecker and Liao, 2005; Wu et al., 1996; Zeldin et al., 
1995).  
Biological Functions of Epoxyeicosatrienoic Acids. The EETs and other P450-
catalyzed metabolites of AA are considered to be autocrine/paracrine mediators because 
these compounds act on the same cell or a neighboring cell of the cell from which they 
were secreted. The concentration of EETs is mostly regulated by their lipophilicity, 
protein binding, and rapid incorporation into the phospholipids of several cell types 
(Karara et al., 1991; VanRollins et al., 1996; Widstrom et al., 2001; Wu et al., 1996). 
Thus, these factors keep the tissue concentrations of these eicosanoids higher near their 
sites of formation than the levels found in plasma, urine, or interstitial fluid (Roman, 
2002). Lipid extracts from human tissues have shown that the levels of incorporation of 
the EETs into membranes may reach micromolar levels (Karara et al., 1991). Biological 
stimuli that activate phospholipases, such as vasoactive hormones, can trigger the release 
of the EETs from membrane-bound phospholipids. This evidence may be indicative of 
the biological fates of structurally similar compounds. Physiologically active EETs have 
several different effects on the body that include effects on cardiovascular tone, 
inflammation, thrombolytic activity, and angiogenesis. 




 (KCa) channels and 




factors (EDHFs) in vascular smooth muscle cells (Campbell et al., 1996; Fleming, 2004; 
Harder et al., 1995). Likewise, EETs can directly and indirectly affect other ion channels 
including L-type Ca
2+
 channels, ATP-sensitive K
+
 channels (K(ATP)), and Na
+
 channels 
(Lee et al., 1999; Lu et al., 2001; Seubert et al., 2004; Xiao et al., 1998; Xiao et al., 
2004). Xiao and coworkers reported that the EETs increase cardiac L-type Ca
2+
 currents 
in ventricular myocytes utilizing a mechanism which involves cAMP-protein kinase A-
dependent phosphorylation of L-type Ca
2+
 channels (Xiao et al., 1998; Xiao et al., 2004). 
The 11,12- and 8,9-EET regioisomers are potent activators of (K(ATP)) and can reduce 
the sensitivity of the channels to ATP in rat cardiomyocytes (Lu et al., 2001). Moreover, 
the cardioprotection observed in transgenic mice with cardiomyocyte-specific 
overexpression of CYP2J2 involves the activation of mitochondrial (K(ATP)) channels 
and the p42/p44 MAPK pathway (Seubert et al., 2004). The EETs, especially 8,9-EET, 
act as potent Na
+
 channel inhibitors by decreasing the probability of the Na
+
 channel 
opening (Lee et al., 1999).  
EETs exhibit anti-inflammatory effects similar to those observed for members of 
the peroxisome proliferator-activated receptor (PPAR) family (Liu et al., 2005; Node et 
al., 1999). The EETs and PPARα inhibit NF-κB activation and vascular cell adhesion 
molecule-1 (VCAM-1) expression (Node et al., 1999; Rival et al., 2002). In addition to 
PPARγ activation, 14,15-, 11,12-, and 8,9-EET have been shown to inhibit 
cyclooxygenase activity (Fitzpatrick et al., 1986; Mendez and LaPointe, 2003). While 
11,12-EET is believed to activate PPARα directly, PPARγ is thought to be an effector of 
the EETs (Liu et al., 2005; Ng et al., 2007). EETs and their metabolites may, in fact, be 




similar effects as EETs on the inhibition of cell migration and inflammation (Wray and 
Bishop-Bailey, 2008).  
Utilizing several different pathways, epoxyeicosatrienoic acids can modulate 
thrombolytic activity. At physiological concentrations, EETs, especially 11,12-EET, are 
known to increase tissue plasminogen activator expression and activity via Gαs 
activation, while having no effect on plasminogen activator inhibitor-1 expression (Node 
et al., 2001). Using a mechanism that has yet to be determined, all of the EETs inhibit 
platelet aggregation induced by AA (Fitzpatrick et al., 1986). EETs also inhibit platelet 
adhesion to endothelial cells through a calcium-activated potassium channel dependent 
mechanism (Krotz et al., 2004). Moreover, Zhang et al. (2008) reported that 11,12-
epoxyeicosatrienoic acid activates the L-arginine/nitric oxide pathway in human platelets 
(Zhang et al., 2008). 
EETs are known to inhibit apoptosis and promote cell proliferation and 
angiogenesis in several different models (Askari et al., 2013; Fleming, 2011; Panigrahy et 
al., 2011). EETs employ multiple mechanisms in order to cause these biological 
outcomes, including crosstalk with the epithelial growth factor receptor (EGFR), 
activation of mitogen-activated protein kinase (MAPK) and PI3K/Akt signaling 
pathways, SRC-activation of STAT-3, and increased endothelial nitric oxide synthase 
(eNOS) expression (Chen et al., 2001; Cheranov et al., 2008; Jiang et al., 2007; Michaelis 
et al., 2005; Node et al., 2001; Wang et al., 2003; Wang et al., 2005). Incidentally, these 
same mechanisms that promote cancer-like activities, i.e. cell proliferation and inhibition 
of apoptosis, allow the CYP epoxygenase CYP2J2 to be protective against cardiac stress, 




al., 2009; Nithipatikom et al., 2006; Seubert et al., 2004; Yang et al., 2001; Zhang et al., 
2009). Only the expression of the cardiac-specific CYP2J2, not the expression of 
endothelial-specific CYP2J2, is thought to be beneficial in ischemic-reperfusion injury 
(Askari et al., 2013; Edin et al., 2011; Seubert et al., 2004). However, this benefit in 
ischemic-reperfusion injury is believed to be mediated only by CYP2J2, because 
CYP2C8 and CYP2C9 activities have been shown to be detrimental to cardiac recovery 
due to their production of reactive oxygen species (Edin et al., 2011; Khan et al., 2007). 
Secondary Metabolism of Epoxyeicosatrienoic Acids. In addition to causing 
important biological effects, free epoxyeicosatrienoic acids can undergo secondary 
reactions including: hydration by soluble epoxide hydrolase (sEH); oxidation by 
cyclooxygenase, lipoxygenase, and P450 ω-oxidase enzymes; partial β-oxidation; chain-
elongation; and glutathione conjugation (Figure 1.2). The epoxide metabolites of P450- 
catalyzed arachidonic acid metabolism are usually converted by soluble epoxide 
hydrolase to form dihydroxyeicosatrienoic acids (DHETs), which are generally believed 
to be less biologically active than the precursory epoxides (Imig et al., 1996; Roman, 
2002). However, DHETs are as potent as the EETs in the dilation of canine coronary 
arteries (Oltman et al., 1998). Moreover, 14,15-DHET can activate PPARα in a COS-7 
cell expression system (Fang et al., 2006). The substrate preference for the hydration of 
EETs by rabbit sEH is 14,15-EET > 11,12-EET > 8,9-EET (Zeldin et al., 1993). 
Oxidation. Although 5,6-EET is reported to be a poor substrate for sEH 
(Sisignano et al., 2012; Zeldin et al., 1993), it is readily oxidized by cyclooxygenase in 




  Figure 1.2. Secondary metabolism of epoxyeicosatrienoic acids (EETs). COX, 
cyclooxygenase; CYP, cytochrome P450; EET, epoxyeicosatrienoic acid; DHET, 
dihydroxyeicosatrienoic acid; PG, prostaglandin; sEH, soluble epoxide hydrolase 




Although 5-hydroxy-PGI1 lacks vasodilator activity, 5,6-epoxy-PGE1 is equal to 5,6-EET 
in its ability to stimulate cyclooxygenase-dependent vasodilation (Carroll et al., 1993; 
Carroll et al., 1992). Moreover, 8,9-EET can form 11- and 15-hydroxy-8,9-EET products 
catalyzed by cyclooxygenase (Zhang et al., 1992). The hydroxyepoxyeixosatrienoic acids 
formed from the 12-lipoxygenase metabolism of 11,12-EET are called hepoxilins and 
they can induce glucose-dependent insulin secretion in pancreatic islets (Pace-Asciak et 
al., 1983; Pace-Asciak and Martin, 1984). Likewise, 15-LOX catalyzes the formation of 
11-hydroxy-14,15-EET and 15-hydroxy-11,12-EET from 14,15- and 11,12-EET, 
respectively, and their trihydroxyeicosatrienoic acid derivatives (Pfister et al., 1998). 
Finally, all four EET isomers can undergo ω- and ω-1 hydroxylation catalyzed by 
CYP4A1 and CYP4A2 (Cowart et al., 2002). The 20-hydroxylation metabolites of 8,9-, 
11,12-, and 14,15-EET all activate PPARα (Cowart et al., 2002). With a Ki of 3 nM at 
PPARα, the 20-hydroxy-14,15-EET may be an endogenous ligand for this receptor 
(Cowart et al., 2002).  
Alternative Metabolism Routes. In human skin fibroblasts, instead of being 
metabolized to form DHETs, the 8,9-, 11,12- and 14,15-EETs primarily undergo 
peroxisomal β-oxidation which shortens the carbon chain of the epoxy fatty acids (Fang 
et al., 2000; Spector et al., 2004). The 14,15-EET forms the 10,11-epoxy-16:2 β-
oxidation product that can relax coronary microvessels that have been contracted with 
endothelin (Fang et al., 2002). In the presence of the sEH inhibitor N,N’-
dicyclohexylurea, porcine coronary endothelial cells produce a chain-elongation product 
of 14,15-EET, 16,17-epoxy-∆
7,10,13
-22:3 which is then incorporated into the lipids of the 




three epoxidated isomers for further conjugation with glutathione; however, the 
biological significance of this pathway has not been investigated (Spearman et al., 1985). 
Drug-Drug Interactions. A drug-drug interaction occurs when the efficacy or 
toxicity of one drug is altered by the administration of a second compound. There are two 
types of drug-drug interactions, pharmacokinetic and pharmacodynamic. 
Pharmacokinetic interactions occur when one drug alters the absorption, distribution, 
metabolism, or excretion of another drug whereas pharmacodynamic interactions occur 
when two drugs have more than additive or opposing effects on the efficacy of one or 
both of the administered drugs. CYPs normally are responsible for pharmacokinetic 
interactions because the metabolizing ability of the respective P450 for one of the two 
drugs is either induced or inhibited by the other drug. For example, grapefruit juice 
contains furanocoumarins that inhibit CYP3A4 activity (Lin et al., 2012). Co-
administration of grapefruit juice with any drug that is metabolized by CYP3A4 will 
result in an increase in the bioavailability of that drug due to the inhibition of CYP3A4-
catalyzed metabolism by the grapefruit juice. Because the EETs are deeply involved in 
the maintenance of normal cardiac function, a drug interaction that disrupts arachidonic 
acid metabolism may alter the bioavailability of these eicosanoids in the cardiovascular 
system and have the potential to cause adverse or to enhance beneficial effects.  
The Endogenous Cannabinoid System (ECS).  The ECS is a lipid signaling 
system which consists of specific receptors, ligands, and the enzymes required to regulate 
the degradation of those ligands (Mouslech and Valla, 2009). Two seven transmembrane 
G-protein coupled receptors have been designated as members of this system, 




receptors can be exogenous, plant-derived or synthetic, or endogenous (DiMarzo et al., 
2004). Moreover, several enzymes are known to participate in the synthesis and 
degradation of cannabinoid ligands (Di Marzo and Deutsch, 1998). Interestingly, the ECS 
and CYP2J2 are coexpressed in several organs including, but not limited to, the brain, 
liver, bladder, and the intestine (Mackie, 2008; Pacher et al., 2006). Because CYP2J2 can 
catalyze the oxidation of a variety of different compounds, its vicinity to ECS ligands 
such as anandamide may allow it to regulate the physiological fates of ECS ligands via 
oxidation. 
The research described in this thesis is primarily focused on the ability of CYP2J2 
to participate in the regulation of the endogenous cannabinoid system (ECS) by 
participating in the metabolic fates of some of its ligands. To complete this task, we 
investigated the metabolism of the endogenous cannabinoid anandamide (AEA) and the 
synthetic cannabinoid JWH-018 by purified CYP2J2 and microsomes prepared from drug 
metabolizing organs reported to express CYP2J2 or other members of the CYP2J family. 
The ECS, including AEA, is known to play a role in energy balance (Matias et al., 2006). 
Due to the connection between AEA and food intake, we have also investigated the effect 
of diet and obesity on the metabolism of AEA. Moreover, in order to better understand 
the possible importance of the epoxyeicosatrienoic acid ethanolamides (EET-EAs), the 
products formed from AEA metabolism by CYP2J2 and other P450s, we studied several 
soluble epoxide hydrolase inhibitors for their ability to prevent the hydrolysis of EET-
EAs. Likewise, we also investigated the cardiovascular effects of JWH-18 administration 
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Cytochrome P450 2J2-Catalyzed Metabolism of Anandamide and the Effects of 
Obesity and Diet on Anandamide Metabolism in the Liver 
 
Abstract 
One in three adults in America is obese. Obesity contributes to the development 
of several other medical conditions such as diabetes and atherosclerosis. Increased 
plasma concentrations of the endogenous cannabinoid anandamide (AEA) have been 
observed in obese individuals. Moreover, fatty acid amide hydrolase (FAAH), the 
enzyme responsible for the hydrolysis of AEA, exhibits decreased activity in obesity. As 
a result, the probability of AEA being metabolized by other drug metabolizing enzymes 
such as cytochrome P450s is increased. The role of AEA in energy balance involves the 
brain and the peripheral organs associated with energy intake including the intestine and 
the liver. Because of this, it is important to investigate AEA metabolism in these relevant 
drug metabolizing organs. CYP2J2 is involved in the metabolism of various 
antihistamines and other drugs in the intestines and may also contribute to intestinal 
metabolism of AEA. The studies reported here demonstrate that purified human CYP2J2 
metabolizes AEA to form the 20-hydroxyeicosatetraenoic acid ethanolamide (HETE-EA) 
and several epoxygenated products including the 5,6-, 8,9-, 11,12-, and 14,15-
epoxyeicosatrienoic acid ethanolamides (EET-EAs) in the reconstituted system. Kinetic 




µM and that the kcat values range from 0.2-23.3 pmol/min/pmol of CYP450. The catalytic 
turnover was 7.12 pmol of total product formed/pmol of CYP450/min at 37°C. Human 
intestinal microsomes metabolize AEA to 20-HETE-EA, 5,6-, 8,9-, and 11,12-EET-EAs 
with apparent Km values of 141, 312, 495, and 1700 µM and Vmax values of 602, 4.4, 4.3, 
and 30 pmols/min/mg of protein, respectively; however, inhibition studies suggest that 
CYP2J2 is not a major contributor to intestinal AEA metabolism. In addition, studies 
using rat liver microsomes suggest that obesity and diet may have significant effects on 
AEA metabolism in the liver. 
 
Introduction 
 According to the Centers for Disease Control and Prevention, a little over 35% of 
the adults in the United States are obese. Moreover, it is estimated that 17% of children, 
aged 2-19 years, are obese. Obesity contributes to several health concerns including heart 
disease, type 2 diabetes, stroke, and some cancers. Obesity occurs when an imbalance 
between food intake and energy expenditure exists and this energy imbalance results in 
excessive fat accumulation in organs involved in metabolism (Ahima, 2008). Evidence 
suggests that modifications in the endocannabinoid system (ECS), consisting of the 
cannabinoid receptors, their endogenous ligands, and the enzymes that regulate the 
synthesis and degradation of those ligands, can be correlated with several pathological 
conditions, including a variety of immunological, cardiovascular, gastrointestinal, and 
metabolic disorders that exhibit altered tissue concentrations of anandamide (AEA) or 2-




and Demorrow, 2009; Ashton and Smith, 2007; Bifulco et al., 2007; Di Marzo, 2008; Di 
Marzo et al., 2004; Lambert, 2007; Storr and Sharkey, 2007). 
 AEA and other ECBs are signaling mediators that  increase appetite by activating 
the cannabinoid 1 receptor (CB1R) (Matias et al., 2006a). The ECS has been identified in 
the brain and peripheral tissues involved in energy balance including, but not limited to, 
the hypothalamus, skeletal muscles, myenteric neurons and epithelial cells of the 
intestine,  and the liver (Pertwee, 1999). In the hypothalamus, ECBs activate CB1Rs to 
inhibit excitatory and inhibitory neurotransmission in several areas of the brain including 
those associated with food consumption and leptin signaling (Cota et al., 2003b; Di 
Marzo et al., 2001; Schlicker and Kathmann, 2001). Activation of the ECS leads to 
increased body weight, lipogenesis, and defective glucose uptake into skeletal muscle 
(Cota et al., 2003a; Eckardt et al., 2009). Likewise, activation of presynaptic CB1Rs in 
neurons and nerve fibers of the stomach, small intestine, and colon decreases gastric acid 
secretion and intestinal motility and secretion through inhibition of acetylcholine release 
(Di Carlo and Izzo, 2003; Kulkarni-Narla and Brown, 2000, 2001; Mascolo et al., 2002; 
Pinto et al., 2002). Overactivation of the ECS in the liver increases liver fat and 
lipogenesis, in particular VLDL (very low density lipoprotein) which is consider to be 
“bad” cholesterol (Nesto and Mackie, 2008). 
Several studies have shown that overweight and obese individuals have higher 
levels of circulating endocannabinoids, e.g. AEA and 2-AG (Annuzzi et al., 2010; Engeli 
et al., 2005; Naughton et al., 2013). In general, the Western diet is considered to be a 
high-fat diet that is rich in linoleic acid (LA), the biosynthetic precursor to arachidonic 




lead to elevated levels of endogenous endocannabinoids and induce weight gain and 
inflammation (Alvheim et al., 2012; Alvheim et al., 2013; Kim et al., 2013; Matias et al., 
2008). The elevated endogenous cannabinoid levels are believed to contribute to the 
overactivation of the ECS observed in obesity and to aggravate the severity of obesity-
related complications (Cote et al., 2007; Matias et al., 2006b). 
AEA normally undergoes hydrolysis by fatty acid amide hydrolase (FAAH) to 
form AA and ethanolamide. However, the elevated levels of AEA observed in obese 
subjects are correlated with a decrease in FAAH activity (Engeli et al., 2005). As a result, 
it is likely that other mechanisms of anandamide metabolism may be more important in 
obesity. AEA can also be oxidized by cyclooxygenases (COX) (Kozak et al., 2002; Yu et 
al., 1997), lipoxygenases (LOX) (Hampson et al., 1995; Ueda et al., 1995), and 
cytochrome P450s (CYP450s) (Snider et al., 2007; Snider et al., 2008; Sridar et al., 2011; 
Stark et al., 2008).  
CYP450s are a superfamily of mono-oxygenases that are involved in the 
metabolism of a wide variety of endogenous and exogenous compounds. The metabolism 
of AEA by human cytochrome P450s is known to give the following metabolites: 19- and 
20-hydroxyeicosatetraenoic acid ethanolamides (HETE-EAs) and 5,6-, 8,9-, 11,12-, and 
14,15-epoxyeicosatrienoic acid ethanolamides (EET-EAs) (Alberich Jorda et al., 2004; 
Pratt-Hyatt et al., 2010; Snider et al., 2007; Snider et al., 2009; Snider et al., 2008; Sridar 
et al., 2011; Stark et al., 2008). CYP2J2 is a CYP450 epoxygenase that is mainly 
expressed in the cardiovascular system (Wu et al., 1996), but it is also expressed in the 
intestines (Paine et al., 2006; Wu et al., 1996), lung (Zeldin et al., 1996), pancreas (Zeldin 




brain (Dutheil et al., 2009), salivary ducts,  and stomach (Enayetallah et al., 2004). 
CYP2J2 metabolizes arachidonic acid (AA) to give 5,6-, 8,9-, 11,12-, 14,15-
epoxyeicosatrienoic acids (EETs) and several minor hydroxyeicosatetraenoic acids 
(HETEs) (Wu et al., 1996); however, its ability to metabolize AEA has not yet been 
investigated.  CYP2J2 is involved in the intestinal metabolism of the non-sedating 
antihistamines ebastine and astemizole and may contribute to AEA metabolism in the 
intestine (Hashizume et al., 2002; Matsumoto et al., 2002). This chapter provides 
information on the metabolism of AEA by purified CYP2J2 in the reconstituted system. 
Because our lab has previously investigated AEA metabolism by human liver 
microsomes, we investigated AEA metabolism by human intestine microsomes in order 
to study AEA metabolism in peripheral organs involved in energy balance (Snider et al., 
2007). In order to determine if obesity and diet affect AEA metabolism, we also 
compared AEA metabolism by liver microsomes derived from rats susceptible or 
resistant to diet-induced obesity. This rat model was developed by Dr. Barry E. Levin 
(Rutgers New Jersey Medical School, Newark, NJ) by selectively breeding rats for the 
propensity to gain weight when fed a moderately fatty diet (Levin et al., 1997). 
 
Methods and Materials 
Materials. AEA, AEA-d8, 5,6-EET-EA, 8,9-EET-EA, 11,12-EET-EA, 14,15-
EET-EA, 20-HETE-EA, and 12-(3-admantan-1-yl-ureido) dodecanoic acid (AUDA) 
were purchased from Cayman Chemical (Ann Arbor, MI). Danazol was purchased from 




diphenyliodonium chloride were purchased from Sigma (St. Louis, MO). All other 
reagents were of the highest quality and were obtained from commercial sources. 
Enzymes. The human CYP450 CYP2J2 cDNA was a gift from Dr. Rheem Totah 
(University of Washington, Seattle, WA). CYP2J2 and CYP450 reductase were 
expressed in Escherichia coli and purified as previously described (Hanna et al., 1998; 
Smith et al., 2008). Human intestinal microsomes were purchased from BD Biosciences 
(Woburn, MA). 
Preparation of Microsomes from Rat Livers. The rat livers were a gift from Dr. 
Carrie Ferrario (University of Michigan, Ann Arbor, MI). The diet resistant (DR) and 
diet-induced obese (DIO) rats from which these livers were collected were originally 
purchased from Taconic (Germantown, NY). The preparation of microsomes was 
performed as described previously (Lin et al., 1998). Briefly, rat livers were chopped and 
subsequently homogenized using a Tissue Tearor (Biospec Product Inc.) in 
homogenization buffer (100 mM potassium phosphate buffer, pH 7.4, 1 mM EDTA, and 
150 mM KCl). The homogenate was centrifuged at 10,000 g for 30 min and the 
supernatant was filtered through gauze to remove the fat. The supernatant was then 
ultracentrifuged at 100,000 g for 75 min. The resulting pellet was resuspended using a 
glass pestle in a Dounce homogenizer in pyrophosphate buffer (100 mM tetrasodium 
pyrophosphate, pH 7.4, and 1 mM EDTA) to remove hemoglobin. The homogenate was 
centrifuged again at 100,000 g for 75 min and the resulting pellet was resuspended in 
suspension buffer (100 mM potassium phosphate buffer, pH 7.4, 1 mM EDTA, and 20% 
glycerol). Bovine serum albumin was used as the standard for the BCA Protein Assay 




microsomes and the reduced CO difference spectrum was used to determine the P450 
concentration (Omura and Sato, 1964). Briefly, microsomes (50 µL) were suspended in 
0.1 M phosphate buffer, pH 7.4, containing 20% glycerol to a total volume of 0.5 mL in a 
1 cm
2
 cell. The microsomes were reduced by the addition of a few milligrams of sodium 
dithionite and an absorbance baseline was measure using a Shimadzu UV-Vis recording 
spectrophotometer UV-2501PC. The solution was bubbled with CO for 30 s and the 
absorbance measured again. The Beer-Lambert Law (A = εbc) was used to calculate the 
concentration “c”, where “A” is the difference in absorbance between baseline and the 






AEA Metabolism Assays. CYP2J2 was reconstituted with reductase (1:2 ratio) in 
lipid (L-α-dilauroyl-phosphocholine) on ice for 60 min as described previously (Snider et 
al., 2007; von Weymarn et al., 2004). The metabolism of anandamide was determined 
using incubation mixtures (0.5 mL) containing 100 mM potassium phosphate buffer (pH 
7.4), catalase, anandamide (1.25-50 µM), and reconstituted CYP2J2 (50 pmols). For 
microsomal studies, 200 µg aliquots of microsomal protein were combined with 100 mM 
potassium phosphate buffer, pH 7.4, 3.3 mM MgCl2, and anandamide in the presence or 
absence of the P450 inhibitors, danazol (100 nM) for CYP2J2, ketoconazole (1 µM) for 
CYP3A4 and sulfaphenazole for CYP2C9 (10 µM), in a final volume of 0.25 mL. 
Reactions were initiated by the addition of 1 mM (recombinant) or 1.3 mM (microsomes) 
NADPH and allowed to continue with shaking for 25-30 min at 37°C. Control reactions 
were performed in the absence of NADPH. The reactions were terminated by the addition 




the samples were vortexed for 2 min and centrifuged at full speed using a desktop 
centrifuge for 5 min. The organic layer was collected and dried down under a constant 
stream of nitrogen gas. The dried samples were resuspended in 100 µL of methanol and 
10 µL aliquots were subjected to electrospray ionization-liquid chromatography/mass 
spectrometry (ESI-LC/MS) analysis. The standard curves for the various metabolites that 
were used for the quantification and determination of the KM and kcat values were 
generated by subjecting various known amounts of authentic standards to the same 
sample workup and ESI-LC/MS analysis. 
ESI-LC/MS Analysis. Samples (10 µL) were injected onto a Hypersil ODS 
column (5 µm, 4.6 × 100 mm; Thermo Fisher Scientific, Waltham, MA) that had been 
equilibrated with 25% solvent A (0.1% acetic acid in water) and 75% solvent B (0.1% 
acetic acid in methanol). The metabolites were resolved using the following gradient: 0 to 
5 min, 75% B; 5 to 20 min, 75 to 100% B; 20 to 25 min, 100% B; 25 to 26 min, 100 to 
75% B; and 26 to 30 min, 75% B. The flow rate was 0.3 ml/min. The column effluent 
was directed into the LCQ mass analyzer (Thermo Fisher Scientific). The ESI conditions 
were as follows: sheath gas, 90 arbitrary units; auxiliary gas, 30 arbitrary units; capillary 
temperature, 200°C; and spray voltage, 4.5 V. Data were acquired in positive ion mode 
for anandamide and its metabolites using the Xcalibur software package (Thermo Fisher 
Scientific) with one full scan from 300 to 500 mass/charge ratio (m/z) followed by one 
data-dependent scan of the most intense ion.  
Data Analysis. Nonlinear regression analyses of the data were performed using 






Metabolism of Anandamide by Human Recombinant CYP2J2. Arachidonic 
acid (AA) is metabolized by recombinant CYP2J2 to form four regioisomeric EETs (Wu 
et al., 1996). As shown in Figure 2.1, AEA is very similar to AA in structure. AA is 
required for the biosynthesis of AEA. The AEA precursor, N-arachidonyl-
phosphatidylethanolamine (NAPE), is formed when the calcium-dependent enzyme, N-
acyltransferase, catalyzes the transfer of AA from the sn-1 position of a 
glycerophospholipid to the amino group of phosphatidylethanolamine (Snider et al., 
2010; Wang and Ueda, 2009).  The precursor can then be converted to AEA via several 
pathways that have been reviewed in the literature (Hansen et al., 2000; Jin et al., 2009; 
Schmid et al., 1990; Snider et al., 2010), but the most direct pathway is catalyzed by a 
NAPE-specific phospholipase D (Okamoto et al., 2009). Due to the similarities between 
the structures of AEA and AA, and the fact that AEA is a substrate for several other 
CYP450s including CYP2D6, CYP3A4, and CYP2B6 (Omura and Sato, 1964; Snider et 
al., 2007; Snider et al., 2008; Sridar et al., 2011), we investigated the possibility that 
anandamide could also be a substrate for CYP2J2. 
Figure 2.2 shows the extracted ion chromatograms for the metabolism of 
anandamide by purified human CYP2J2. Figure 2.2 (Top) is the extracted ion 
chromatogram at m/z 348 and it shows the positive ion formed by anandamide in the 
mass spectrometer which eluted at 23.6 min under the LC/MS conditions described in 
Materials and Methods. The bottom chromatogram shows the five mono-oxygenated 





Figure 2.1. Structures of arachidonic acid and anandamide. Arachidonic 
acid and anandamide are identical in structure with the exception that 
arachidonic acid has a hydroxyl group on carbon one while anandamide has 




  Figure 2.2. AEA metabolism by CYP2J2. Purified CYP2J2 was reconstituted with reductase 
(1:2 ratio) in 10 µg of lipid (L-α-dilauroyl-phosphocholine) on ice for 30 min. The 
reconstituted enzyme (15 µL) was added to the incubation mixture (0.5 mL) containing 100 
mM potassium phosphate buffer (pH 7.4), anandamide (10 µM), and catalase. Reactions were 
initiated by the addition of 1 mM of NADPH and allowed to continue with shaking for 30 min 
at 37°C. The reactions were terminated, metabolites extracted, and products analyzed by ESI-
LC/MS as described in Materials and Methods. The extracted ion chromatogram observed at 
m/z 348, shows the parent ion, anandamide, eluting at 23 min (Top). The extracted ion 
chromatogram observed at m/z 364, shows the monooxygenated product peaks which elute at 
approximately 15.3, 18.2, 19.1, 19.7, and 20.6 min for 20-HETE-EA, 14,15-, 11,12-, 8,9-, and  
5,6-EET-EA, respectively (Bottom). Product identity was verified by comparing the retention 





2.2). Based on their retention times and fragmentation patterns when compared with 
authentic standards (data not shown), the metabolites were identified as 20-HETE-EA, 
14,15-, 11,12-, 8,9-, and 5,6-EET-EAs, respectively. Four di-oxygenated products  
were observed in the extracted ion chromatogram at m/z 380 (Figure 2.3) which eluted at 
approximately 8, 11, 13, 14, and 16 min; however, these products could not be 
unequivocally identified due the lack of commercially available di-oxygenated AEA 
metabolites. 
Kinetic Studies on the Metabolism of Anandamide by Human Recombinant 
CYP2J2. The reaction conditions used to determine the kinetic constants, KM and kcat, for  
the hydroxylation and epoxygenation of anandamide by purified CYP2J2 were shown to 
be linear with respect to protein concentration (up to 25 pmols) and time of incubation 
(up to 25 min) (data not shown). As shown in Figure 2.4, the metabolism of anandamide 
exhibited typical Michaelis-Menten kinetics for the formation of 20-HETE-EA and 5,6-, 
8,9-, 11,12-, and 14,15- EET-EAs. The observed KM values calculated from the data in 
Figure 2.4 using GraphPad Prism 6 software were 10, 468, 104, 101, and 103 µM and the 
kcat values were 0.2, 23.3, 3.6, 4.1, and 6.9 pmol/min/pmol of CYP450, respectively. The 
efficiency of the enzyme for the formation of all five metabolites, as measured by the 
kcat/KM values, was relatively the same for all products formed with values of 0.02, 0.05, 
0.03, 0.04, and 0.07 for the 5,6-, 8,9-, 11,12-, 14,15-EET-EAs, and 20-HETE-EA, 
respectively. 
 AEA Metabolism by Human Intestinal Microsomes. Because the intestine is 




  Figure 2.3. Formation of di-oxygenated metabolites of AEA by CYP2J2. Recombinant 
CYP2J2 was reconstituted with reductase (1:2 ratio) in lipid (L-α-dilauroyl-phosphocholine) 
on ice for 30 min. The enzyme source (15 µL) was added to the incubation mixture (0.5 mL) 
containing 100 mM potassium phosphate buffer (pH 7.4), anandamide (50 µM), and catalase. 
Reactions were initiated by the addition of 1 mM of NADPH and allowed to continue for 30 
min at 37°C. The metabolites were extracted and analyzed as described previously in 
Materials and Methods. The extracted ion chromatogram observed at m/z 380, shows that at 
least three di-oxygenated products are formed (A). The fragmentation patterns for the three 






Figure 2.4. Kinetic analysis of anandamide metabolism by purified CYP2J2. Varying 
concentrations of anandamide (1.25-50 µM) were metabolized by reconstituted CYP2J2 
(25 pmol) for 25 min at 37°C. The symbols for the metabolites are: 14,15-EET-EA (■), 
11,12-EET-EA (▲), 8,9-EET-EA (▼), 5,6-EET-EA (♦), and 20-HETE-EA (●). Standard 
curves were generated for each metabolite to determine the amount of product formed. 








human intestinal microsomes (HIM) to metabolize AEA. Incubations containing 200 µg 
of HIM were used to metabolize AEA for 30 min at 37°C as described in Materials and 
Methods. Figure 2.5 shows all the metabolites formed from AEA metabolism by HIM. 
Figure 2.5 (Top) shows the extracted ion chromatogram at m/z 364 for the metabolites 
from this reaction with peaks eluting at 15.9, 18.4, 19.2, 19.8, and 20.7 min, which 
correspond to 20-HETE-EA,  14,15-, 11,12-, 8,9-, and 5,6-EET-EAs, respectively. 
Although no standard is commercially available for positive identification of this product, 
the product eluting at 17.3 min is thought to be 19-HETE-EA (Pratt-Hyatt et al., 2010; 
Snider et al., 2007; Snider et al., 2009). The peaks eluting at 11.6, 13.4, and 15.6 min 
observed at m/z 382 correspond to the diols formed when the epoxides (m/z 364) are 
hydrolyzed (Figure 2.5 (Bottom)). Evidence to support this can be seen with the increase 
of epoxide formation and the decrease in diol formation in the presence of AUDA (10 
µM), a soluble epoxide hydrolase inhibitor (dashed line) (Morisseau and Hammock, 
2013). 
Figure 2.6 shows the kinetic curves for the products formed by the metabolism of 
AEA by intestinal microsomes. Two different kinetic models were utilized to determine 
the Km and Vmax for 20-HETE-EA, 5,6-, 8,9-, and 11,12-EET-EAs. The levels of 14,15-
formation under these conditions were too low to calculate accurate values for the kinetic 
constants. Likewise, the kinetic information for 19-HETE-EA could not be calculated 
because there is no standard available for this metabolite. Double reciprocal plots were 
used to determine the kinetic constants for the EET-EAs and the formation of 20-HETE-
EA followed Michaelis-Menten kinetics. The Km values for 20-HETE-EA, 5,6-, 8,9-, and 








Figure 2.5. AEA metabolism by HIM in the presence and absence of AUDA. Human 
intestinal microsomes (200 µg) were incubated with anandamide (25 µM) for 30 min at 37°C 
and the metabolites were extracted and analyzed as described in Materials and Methods. The 
extracted ion chromatograms for the mono-oxygenated products (m/z 364, Top) and the diols 
formed by the hydrolysis of the epoxides (m/z 382, Bottom) are shown. The dashed lines 
represent the chromatogram observed in the presence of 10 µM of AUDA, a soluble epoxide 






Figure 2.6. Kinetics for the metabolism of AEA by HIM. Human intestinal protein 
(0.8 mg/mL) was reacted with AEA (5-1400 µM) in 0.1 M potassium phosphate 
buffer containing MgCl2. The reaction was initiated with NADPH (1.3 mM) and 
incubated at 37°C for 30 min with agitation. The reaction was quenched with 1 mL of 
ice cold ethyl acetate and the metabolites were extracted and prepared for analysis as 
described in Materials and Methods. The double reciprocal plot was used to 
determine the kinetic parameters for 11,12-EET-EA (∎) (A), 8,9-EET-EA (▲) (B), 
and 5,6-EET-EA (▼) (C). A Michaelis-Menten kinetic plot was used to determine the 
kinetic parameters for 20-HETE-EA (●) (D). The data were plotted using the 




calculated were 602, 4.4, 4.3, and 30 pmols/min/mg of protein for 20-HETE-EA, 5,6-, 
8,9-, and 11,12-EET-EAs, respectively.  
Contribution of Individual P450s to the Metabolism of AEA by HIM. Several 
cytochrome P450s are expressed in the intestines at detectable levels including CYP3A4, 
CYP2C9, and CYP2J2 (Paine et al., 2006). Selective chemical inhibitors for CYP3A4 
(ketoconazole), CYP2C9 (sulphaphenazole), or CYP2J2 (danazol) (Lee et al., 2012) were 
used to determine the relative contribution of each P450 to AEA metabolism in the 
intestine. In the absence of AUDA, no detectable amount of 14,15-EET-EA was formed 
at the concentration of AEA used for this experiment; however, 11,12-, 8,9-, and 5,6-
EET-EAs were formed in addition to 19- and 20-HETE-EA. The bar graph in Figure 2.7 
displays the changes in the formation of various mono-oxygenated products in the 
presence of the selective P450 inhibitors, while Table 2.1 shows the numerical values.  
Based on the decrease in product formation after inhibition of selected P450 activity as 
compared to control, only CYP2C9 and CYP3A4 appear to contribute significantly to the 
formation of 11,12-EET-EA and 20-HETE-EA, respectively (Figure 2.7 and Table 2.1). 
 Changes in the Metabolism of AEA in Obese Rats. To determine if there is a 
difference in AEA metabolism as a result of obesity, liver microsomes were made from 
diet-induced obese (DIO) rats and diet-resistant (DR) rats as described in Materials and 
Methods. In addition, we studied the difference in AEA metabolism in rats fed a normal 
diet (ND) and rats fed a junk food diet (JFD). Interestingly, rat liver microsomes (RLM) 
do not form the traditional P450-mediated EET-EAs and HETE-EAs from AEA seen 
with human liver microsomes. The candidates selected for monitoring had to fit the 




  Figure 2.7. Contributions of individual P450s to AEA metabolism by HIM. The HIM 
(200 µg) were incubated with anandamide (100 µM) for 30 min at 37°C in the presence 
of vehicle, the selective CYP3A4 inhibitor ketoconazole (1 µM), the selective CYP2C9 
inhibitor sulfaphenazole (10 µM), or the selective CYPJ2 inhibitor danazol (100 nM). 
The reactions were quenched with ice cold ethyl acetate and the metabolites were 
extracted and analyzed as described in Materials and Methods. (A) Epoxide formation 
in pmols/min/pmols of P450, (B) hydroxylated products formed in pmols/min/pmols of 
P450. Statistical significance determined by GraphPad Prism 6 Program using the 
Holm-Sidak method, *, P < 0.05; ***, P < 0.001. Each bar represents the mean ± SEM 




Table 2.1. Numerical values for product formation by P450s in the presence of specific 
inhibitors. The control column shows the amount of each product formed in the presence 
of vehicle. The CYP2C9, CYP3A4, and CYP2J2 columns show the amount of product 
formed in the presence of the selective inhibitors sulfaphenazole (10 µM), ketoconazole 
(1 µM), and danazol (100 nM), respectively. The compounds and concentrations used 
were previously shown to be effective at inhibiting the respective P450 (Hashizume et 
al., 2002; Lee et al., 2012). The values are taken directly from the bar graphs in Figure 




(2) the presence of selective inhibitors for COX and LOX did not inhibit formation, and 
(3) the presence of an inhibitor of the NADPH-cytochrome P450 reductase decreases its 
formation. Figure 2.8 shows a bar graph for the three P450-mediated products, M7, M8, 
and M9, that were selected to be monitored to compare differences in P450 activity in 
obese vs. lean animals and animals on a normal diet vs. a junk food diet. Two of the 
metabolites are observed at m/z 356 and elute at 16.6 (M7) and 17.5 min (M8). The third 
product is observed at m/z 380 and elutes at 22 min (M9). 
The rats used for this experiment were 65 days old upon arrival and both DR and 
DIO rats were fed a ND. At 120 days of age, some DR rats were fed a JFD while another 
group of DR rats continued on the ND. Likewise, some DIO rats continued on a ND 
while others started the JFD. Rats continued on the ND or the JFD for an additional 40 
days until they were sacrificed and the livers were harvested. All rats had free access to 
either the ND, standard lab chow (Purina Lab Diet 5001: 4.5% fat, 23% protein, 6.2% 
sugar; 4 kcal/g), or the JFD, a mashed mixture of 40 g of potato chips, 130 g of peanut 
butter, 40 g of chocolate chip cookies, 130 g of Nesquik powdered chocolate flavoring, 
and 200 g of standard lab chow (19.6% fat, 14% protein, 25.7% sugar; 4.5 kcal/g). The 
average weight of the rat model on the different diets is as follows: DIO rats fed JFD > 
DIO rats fed ND > DR rats fed JFD > DR rats fed ND. In addition to the differences in 
weight, DIO rats fed the JFD also exhibited glucose intolerance and relative insulin 
resistance (Levin et al., 1997). 
Rat liver microsomes derived from DR rats fed a ND, DR rats fed a JFD, and DIO 






Figure 2.8. Determination of P450-mediated metabolites formed by rat liver 
microsomes. Anandamide (100 µM) was incubated with RLM (200 µg) in the 
presence of vehicle or 10 µM of indomethacin, a COX inhibitor (data not shown), 
nordihydroguaiaretic acid, a LOX inhibitor (data not shown), 1-
aminobenzotriazole, a P450 inhibitor (data not shown), or diphenyliodonium 
chloride (DIC), a P450 reductase inhibitor. The reactions were incubated for 30 
min at 37°C and the products were extracted and analyzed by ESI-LC/MS as 
described in Materials and Methods for products observed at (A) m/z 356 and (B) 
m/z 380. The bar graph represents the peak area ratio (product peak area: AEA-d8 
peak area) for the amount of product formed as the mean ± SEM from two 






Figure 2.9. Effect of obesity and diet on P450-catalyzed metabolism of AEA by RLM. 
Liver microsomes were prepared from Levin rats selectively bred to be susceptible or 
resistant to diet induced obesity on junk food (JFD) and/or normal diet (ND). Rat liver 
microsomal protein (200 µg) was incubated with AEA (100 µM) for 30 min at 37°C and 
product formation was determined as previously described. (A) The extracted ion 
chromatogram of M7 (m/z 356), M8 (m/z 356), and M9 (m/z 380), representative of the 
microsomes made from DR rat on a normal diet (solid line), DR rat on a junk food diet 
(dotted line), or DIO rat on a normal diet (dashed line). The corresponding bar graph 
shows the relative amounts of the monitored P450 products as measured by the peak area 
ratio at m/z 356 (B) and m/z 380 (C). The amount of product formed is the mean ± SEM 
from two separate experiments performed in duplicate. Statistical significance was 
determined using the Holm-Sidak method in the GraphPad Prism 6 Program, *, P < 0.05; 




the extracted ion chromatograms for each of the samples monitoring the three 
aforementioned P450-mediated products at m/z 356 and 380. Figure 2.9B shows bar 
graphs quantifying the information. For products M7 and M8, there was a significant 
increase in product formation by liver microsomes from the DIO rats on a ND when 
compared to the DR rat on either the ND or JFD. On the other hand, there was a 
significant decrease in the formation of M9 by the livers of DR rats fed a JFD and DIO 
rats fed a ND when compared to DR rats fed a ND. 
 
Discussion 
Normally, AEA is hydrolyzed by FAAH to give arachidonic acid and 
ethanolamine; however, AEA can also be oxidized by COX-2, LOX, and CYP450 
enzymes. COX-2 catalyzes the oxidation of AEA to prostaglandin ethanolamides or 
prostamides (Kozak et al., 2002; Ritter et al., 2012; Yang et al., 2005; Yu et al., 1997). 
Prostamide F2α and its analog bimatoprost act at the prostamide receptor to increase hair 
growth, reduce fat disposition, and mediate nociception (Woodward et al., 2013). 
Lipoxygenase converts AEA into several hydroxyanandamides (Hampson et al., 1995). 
12-Hydroxyanandamide, a brain metabolite, has an affinity for the for the CB1 receptor in 
the nanomolar range and can inhibit forskolin-stimulated cAMP production suggesting a 
possible physiological role as well (Hampson et al., 1995). Likewise, cytochrome P450s 
can epoxygenate AEA to give the 5,6-, 8,9-, 11,12-, and 14,15-EET-EAs and hydroxylate 
it to give 20- and 19-HETE-EA (Snider et al., 2007; Snider et al., 2008; Sridar et al., 




To date, the CYP450s known to metabolize AEA are found primarily in the liver, 
kidney, and brain (Snider et al., 2007; Snider et al., 2008; Sridar et al., 2011). CYP2J2 is 
the most abundantly expressed CYP450 in the cardiovascular system (Wu et al., 1996), 
but it is also known to participate in the intestinal metabolism of a couple of non-sedating 
antihistamines (Hashizume et al., 2002; Matsumoto et al., 2002). CYP2J2 metabolizes 
AA, which is structurally similar to AEA, to give four EETs which have a plethora of 
biological actions in the body. Because CYP2J2 plays an important role in the 
metabolism of AA, it is possible that CYP2J2 might play an important role in the 
metabolism of AEA as well. This study was performed to investigate CYP2J2 
metabolism of AEA and its involvement in the intestinal metabolism of AEA. Moreover, 
we also investigated the effects of obesity and a junk food diet on AEA metabolism in the 
rat liver. 
We are the first to report that human recombinant CYP2J2 metabolizes AEA to 
give five mono-oxygenated products: the 5,6-, 8,9-, 11,12-, 14,15-EET-EAs and 20-
HETE-EA. This metabolite profile is similar to that reported by other labs for the 
metabolism of AA by recombinant CYP2J2 that yielded the four epoxides, 14,15-, 11,12-
, 8,9-,  and 5,6-EETs, in addition to the several HETEs (King et al., 2002; Wu et al., 
1996). Although CYP2J2 is thought to function primarily as an epoxygenase, it does 
hydroxylate some substrates including AA, terfenadine, and ebastine (Hashizume et al., 
2002; King et al., 2002; Lafite et al., 2006; Wu et al., 1996). Our studies determined the 
kinetic constants, KM and kcat, for each of the five metabolites formed. A caveat for the 




reached saturation even up to 1 mM of AEA (data not shown). As a result, the calculated 
kinetic constants are extrapolated and can only serve as estimated values. 
Although the EET-EAs had different values for their kinetic parameters, similar 
deviations in these kinetic values have been seen for the metabolism of AEA by other 
CYP450s and for the different regioisomers formed during CYP450-mediated 
metabolism of AA (Daikh et al., 1994; Kiss et al., 2000; Pratt-Hyatt et al., 2010; Snider et 
al., 2008; Sridar et al., 2011). Although the metabolism of AEA by CYP2J2 is not as 
efficient, estimated by calculating kcat/KM, as that observed for some of the other P450s 
such as CYP2D6 or CYP2B6, these kinetic parameters are comparable to those reported 
for CYP3A4 (Pratt-Hyatt et al., 2010; Snider et al., 2008; Sridar et al., 2011). In the 
presence of 50 µM AEA, the total catalytic turnover rate for recombinant CYP2J2 was 
calculated to be about 7 nmol of total product formed/nmol of CYP2J2/min. For 
comparison, in the presence of 100 µM AA, two separate labs have determined the 
turnover to be 0.065 and 0.165 nmol of total product formed/nmol of CYP2J2/min (King 
et al., 2002; Wu et al., 1996). Although plasma levels of AA are significantly higher than 
AEA (3-4 mM vs. 300-400 nM), the actual concentrations of AEA in subcellular 
compartments, such as the plasma membrane, are most likely significantly higher (Brash, 
2001; Fernandez-Rodriquez et al., 2004; Shinde et al., 2012). This suggests that AEA 
may be a substrate for CYP2J2 in vivo. 
Several di-oxygenated products were observed at m/z 380 in the extracted ion 
chromatograms of the metabolites formed by recombinant CYP2J2 (Figure 2.3). These 
were minor products compared to the EET-EAs. Because di-oxygenated AEA metabolite 




products formed. CYP2D6 is known to di-oxygenate AEA to form several 
hydroxyepoxyeicosatrienoic acid ethanolamides (HEET-EAs) (Snider et al., 2008). It is 
possible that these CYP2J2-catalyzed products observed at m/z 380 are structurally 
similar. 
The ECS activity in the intestine plays a crucial role in energy balance; therefore, 
it is important to know the identities and relative amounts of the AEA metabolites formed 
in the intestine. The metabolite profile for HIM is similar to that of HLM with the 
formation of 20- and 19-HETE-EAs and 11,12-, 8,9-, and 5,6-EET-EAs (Snider et al., 
2007). However, the formation of the 14,15-EET-EA was only observed using 
concentrations of AEA above 100 µM or in the presence of a soluble epoxide hydrolase 
inhibitor. The efficiencies or Vmax/Km values for the formation of 20-HETE-EA, 5,6-, 
8,9-, and 11,12-EET-EAs were 4, 0.01, 0.009, and 0.02 µL/min/mg of protein. Because 
the presence of AUDA increased the formation of the EET-EAs, this suggests the 
presence of epoxide hydrolase (EH) in HIM preparations. Although it is expected that 
microsomes may contain microsomal EH, AUDA is a soluble EH inhibitor and should 
not inhibit microsomal EH activity (Morisseau and Hammock, 2013). It is likely that the 
inhibition of EET-EAs formation in the presence of AUDA is a substrate competition 
effect and not inhibition of microsomal EH activity; however, it is not impossible for 
some soluble EH activity to be present. Because the EET-EAs are constantly being 
hydrolyzed by EHs, the kinetic constants calculated for HIM may not be entirely reliable. 
The 20-HETE-EA metabolite is the major product of P450-catalyzed AEA metabolism in 
HLM and HIM (Snider et al., 2007). In relation to the epoxides, the 8,9-EET-EA was the 




product formed by HIM although the efficiency for its formation is the same as 11,12-
EET-EA. Although CYP2J2 is present in the intestine, it does not appear to be a 
significant contributor to AEA metabolism in the intestine in comparison with other 
P450s. On the other hand, CYP3A4 and CYP2C9 are responsible for about 50% of the 
20-HETE-EA and 11,12-EET-EA produced in the intestine, respectively. Other P450s 
such as CYP2C19 and CYP2D6, both of which are known to be expressed at appreciable 
levels in the intestine, probably contribute significantly to AEA metabolism in the 
intestine as well (Paine et al., 2006; Snider et al., 2008). A caveat to this study is that no 
test was completed to determine the presence of the P450s; however, the product 
description provided by BD Biosciences reported activity for CYP3A4, CYP2C9, and 
CYP2J2. 
 Plasma AEA levels are positively associated with body mass index. As a result, 
obese individuals exhibit higher concentrations of AEA when compared to lean controls 
(Engeli et al., 2005; Quercioli et al., 2011). An important aspect of obesity is the chronic 
low level inflammation (Kim et al., 2013).The affinity of AEA for the CB1R is four times 
that of its affinity for the CB2 receptor (Felder et al., 1995). CB1 receptor activation is 
believed to be pro-inflammatory, while CB2 receptor activation is thought to be anti-
inflammatory (Han et al., 2009; Rajesh et al., 2008). Thus, the AEA tone may contribute 
to the chronic inflammation associated with obesity. The CB2R is also important in 
intestinal motility, especially during inflammation. Immune cells in the mucosal regions 
of the gastrointestinal tract express CB2 receptors which downregulate leukocyte 
infiltration and inflammation via inhibition of adhesion and migration, apoptosis of 




Klein, 2005; Lunn et al., 2006). The migration of dendritic cells to various inflammatory 
sites is necessary to initiate immune responses and activation of the CB2 receptor can 
inhibit this process. Activation of the CB2 receptor causes a decrease in cAMP levels, 
and as a result, ERK activation decreases causing a decrease in the expression of matrix 
metalloproteinase (MMP-9) which facilitates the migration of inflammatory cells 
(Adhikary et al., 2012). As a result, CB2 receptor activation may be an endogenous 
mechanism  to combat inflammation (Wright et al., 2008). 
Previous studies from our lab have suggested a physiological importance for the 
5,6-EET-EA metabolite of AEA since it has a nanomolar affinity for the CB2 receptor 
and it can decrease intracellular cAMP accumulation in Chinese hamster ovary cells 
expressing the CB2 receptor (Snider et al., 2009). Moreover, this metabolite is more 
biologically stable than the parent AEA with an estimated half-life of 32 min (Snider et 
al., 2009). This half-life is four times longer than the half-life reported for the structurally 
similar 5,6-EET metabolite formed by the metabolism of AA (Fulton et al., 1998). Since 
the 5,6-EET-EA is the major AEA metabolite formed in the intestine, it may play an 
important anti-inflammatory role in the intestine. 
Microsomes prepared from the livers of rats selectively bred to be susceptible or 
resistant to diet-induced obesity were used to determine if obesity and/or diet had any 
effect on AEA metabolism in the liver. The RLM did not form the expected metabolites 
of AEA, the EET-EAs and the HETE-EAs. This may be because rat and human P450s 
are not identical and the liver P450 isomer content may differ as well. One group 
investigated AEA metabolism by mouse brain and liver microsomes (Broheim et al., 




were positively identified. Conversely, the mouse brain formed only two metabolites with 
a positive ion mass of 365. So, it is not unlikely that RLM would form different 
metabolites than HLM. Because RLM did not form the epoxides and hydroxides of AEA 
formed by human P450s, three other P450-mediated metabolites were identified and 
observed for changes in their formation with regard to weight and diet.  
Using the P450 reductase inhibitor DIC, three alternative P450-catalyzed 
metabolites were identified having m/z values at 356 and 380. All P450s require 
reductase as an electron donor in order for metabolism to occur. Although DIC did not 
eliminate all product formation, this can be explained by the use of only one 
concentration of DIC. It is possible that if higher concentrations were used, there would 
be a complete inhibition of product formation. Even though the identities of M7(m/z 
356), M8 (m/z 356), and M9 (m/z 380) were not determined, previous studies suggest that 
AEA metabolites that ionize at m/z 380 are secondary EET-EA products that are 
dioxygenated (Snider et al., 2008).  For the M7 and M8 products, obesity seems to be the 
more important determinant when investigating AEA metabolism than diet. Conversely, 
for the M9 metabolite, the junk food diet seems to have more effect on its formation than 
obesity. 
Increased anandamide levels in overweight people exhibit a correspondence with 
decreased FAAH activity which increases the likelihood of anandamide being 
metabolized via alternative pathways such as by cyclooxygenases, lipoxygenases, and 
P450s (Engeli et al., 2005; Ligresti et al., 2013). However, the expression levels of these 
enzymes are sometimes altered due to inflammation and obesity. Evidence suggests that 




2000; Xu et al., 2005). Since COX metabolizes AA to proinflammatory prostaglandins 
and thromboxanes (PGE2 and TXA2)) which induce the production of inflammatory 
cytokines, such as IL-1β, IL-6, and TNF-α from macrophages, the increase in COX 
activity may promote the inflammatory state observed in obesity (Tilley et al., 2001). 
Likewise, research suggests that LOX activity may be pro-inflammatory as well (Li et al., 
2013; Neels, 2013).  
Conversely, several P450s exhibit decreased expression in animal models of 
obesity and inflammation (Morgan, 1997; Renton, 2001; Wamberg et al., 2013; Zhao et 
al., 2006). Studies utilizing animal models of obesity suggest a decrease in P450 
epoxygenase activity with a concomitant increase in epoxide hydrolase activity, but no 
effect on P450 ω-hydrolase activity (Laffer et al., 2004; Theken et al., 2012a; Zhao et al., 
2005). Moreover, obese individuals have been reported to have a decrease in CYP2J2 
expression in subcutaneous adipose tissue and significantly lower plasma EET levels 
when compared to control subjects (Theken et al., 2012b; Wamberg et al., 2013). 
Because P450s produce pro-inflammatory ω-hydroxylated fatty acids and anti-
inflammatory epoxygenated fatty acids, the decrease in the anti-inflammatory mediators 
may contribute to the inflammation observed in obesity. The impact of a junk food diet 
rich in ω-6 fatty acids on epoxide formation is evident by the altered formation of M9. 
Since RLM did not form the EET-EAs or the HETE-EAs, they are probably not the best 
model to study obesity. However, the important point is that in obesity AEA is increased, 
but P450 activity is likely decreased. This would likely cause a decrease in the anti-
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Inhibition of the Hydrolysis of Epoxyeicostrienoic Acid Ethanolamides Using the 
Soluble Epoxide Hydrolase Inhibitors AUDA, APAU, and TPPU 
 
Abstract 
 The endocannabinoid anandamide is metabolized by several P450s to give four 
epoxyeicosatrienoic acid ethanolamides (EET-EAs). The biological functions of these 
metabolites have yet to be determined. Much progress has been made in understanding 
the purpose of the structurally related metabolites of arachidonic acid, the 
epoxyeicosatrienoic acids (EETs), as a result of the development of soluble epoxide 
hydrolase inhibitors (sEHIs). Soluble epoxide hydrolase (sEH) is the main enzyme 
responsible for the hydrolysis of the epoxide-containing EETs to the less chemically 
reactive dihydroxyeicosatrienoic acids (DHETs). Since it is likely that sEH is also 
responsible for the hydrolysis of EET-EAs to DHET-EAs, it is possible that the same 
sEHIs can be used to inhibit the hydrolysis of the EET-EAs. As a result, the sEHIs 
AUDA, APAU, and TPPU were investigated for their ability to inhibit the hydrolysis of 
the EET-EAs by sEH. The 5,6-, 8,9-, 11,12-, and 14,15-EET-EAs are formed as a result 
of human liver S9 metabolism of AEA. Preliminary kinetic assays determined that for 19- 
and 20-HETE-EAs, the Km values were 199 and 63 µM, respectively, and the Vmax values 
were determined to be 137 and 503 pmols/min/mg of protein, respectively.  Since the 




the rates of formation of the EET-EAs could not be accurately measured since the 
epoxides were also being hydrolyzed rapidly. As a result, the kinetic parameters could 
not be determined. Subsequent studies demonstrated that AUDA had an EC50 value of 5.6 
µM for inhibiting the hydrolysis of 14,15-EET-EA and APAU exhibited EC50 values of 
4.7 and 10.4 µM for inhibiting the hydrolysis of 11,12- and 14,15-EET-EAs, 
respectively. TPPU did not significantly inhibit the hydrolysis of any of the EET-EAs. 
Future studies leading to the design of more specific and potent inhibitors of the epoxide 
hydrolases responsible for EET-EA hydrolysis may be of great value in elucidating the 
biological roles of the EET-EAs.  
 
Introduction 
The endogenous cannabinoid arachidonoyl ethanolamine or anandamide (AEA)  
is oxidized by cytochrome P450s (P450s) to give several different metabolites, including 
the four regioisomeric epoxides 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid 
ethanolamides (EET-EAs) (Snider et al., 2007; Snider et al., 2008; Snider et al., 2010; 
Sridar et al., 2011; Stark et al., 2008). Data suggest that these epoxides are readily 
hydrolyzed by epoxide hydrolases (EHs) to give the 1,2-diols thereby forming the 
corresponding dihydroxyeicosatrienoic acid ethanolamides (DHET-EAs) (Morisseau and 
Hammock, 2005; Snider et al., 2007). As a result of the transitory nature of the epoxides, 
it may be difficult to ascertain their biological functions in the body experimentally. 
Humans have several EHs which are members of the α/β-hydrolase fold family 
and utilize a two-step mechanism to open epoxides and add a water molecule (Morisseau 




notable EH family members, microsomal epoxide hydrolase (mEH) and soluble epoxide 
hydrolase (sEH), respectively (Decker et al., 2009; Morisseau and Hammock, 2005). The 
names of the enzymes correspond to their cellular localization. While mEH is found in 
the smooth endoplasmic reticulum or microsomes, sEH is found in the cytosol and 
peroxisomes (Enayetallah et al., 2006; Hosagrahara et al., 2004). Although mEH is 
primarily known for its ability to catalyze the hydrolysis of epoxides of xenobiotics and 
toxins, it can also hydrolyze fatty acid epoxides such as the EETs; however, sEH is far 
more efficient at catalyzing the hydrolysis of fatty acid epoxides (Marowsky et al., 2009; 
Morisseau et al., 2010; Oesch, 1973). Because of this, it is likely that sEH may be the 
primary enzyme responsible for the hydrolysis of the EET-EAs in vivo. 
 The EET-EAs are structurally similar to the P450-catalyzed arachidonic acid 
(AA) epoxide metabolites, the epoxyeicosatrienoic acids (EETs). These compounds only 
differ by the functional group attached to the α-carbon. While EETs have a hydroxyl 
group attached to the first carbon, EET-EAs have an ethanolamine group attached to the 
corresponding carbon. Experiments utilizing sEH isolated from rabbits determined that 
the EETs are subject to hydrolysis by sEH, but this enzyme prefers the epoxide to be 14-
16 carbons away from the carboxylic acid (Morisseau and Hammock, 2005; Zeldin et al., 
1993). As a result, the 14,15-EET isomer is the preferred substrate, whereas the 5,6-EET 
is an unlikely substrate (Zeldin et al., 1993). Although the EETs are quite labile in vivo 
due to their sEH-mediated hydrolysis to DHETs, a wealth of information is known about 
their biological functions and this can be attributed to commercially available standards, 
reliable quantification methods, and perhaps more importantly, the development of 




Here we describe the first investigation of the abilities of three potent sEHIs for EET 
hydrolysis to prevent the conversion of the EET-EAs to DHET-EAs in human liver S9 
fractions. 
 
Methods and Materials 
Materials. Anandamide, anandamide-d8, 5,6-EET-EA, 8,9-EET-EA, 11,12-EET-
EA, 14,15-EET-EA, and 20-HETE-EA were purchased from Cayman Chemical (Ann 
Arbor, MI). 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU), 12-(3-admantan-1-yl-
ureido) dodecanoic acid (AUDA), and 1-trifluoromethoxyphenyl-3-(1-
propionylpiperidin-4-yl) urea (TPPU) were gifts from Dr. Bruce Hammock (University 
of California-Davis, Davis, CA). Pooled human liver S9 fractions were purchased from 
BioreclamationIVT (Baltimore, MD). All other reagents were of the highest quality and 
were obtained from commercial sources. 
Anandamide Metabolism Assays. The metabolism of anandamide was 
determined using incubation mixtures (0.25 mL) containing human liver S9 fractions (0.8 
mg/mL), 100 mM potassium phosphate buffer (pH 7.4), 3.3 mM MgCl2, and anandamide. 
Varying amounts of APAU, AUDA, and TPPU were added to the reactions as indicated 
in the figure legends. Reactions were initiated by the addition of 1.3 mM NADPH and 
allowed to continue for 20-30 min at 37°C. Control reactions were performed in the 
absence of NADPH. The reactions were terminated by the addition of 1 ml of cold ethyl 
acetate. After the addition of the internal standard, anandamide-d8, the samples were 
vortexed for 2 min and centrifuged at full speed using a desktop centrifuge for 5 min. 




dried down under a constant stream of nitrogen gas. The dried samples were resuspended 
in 100 µL of methanol and 10 µL aliquots were subjected to electrospray ionization-
liquid chromatography/mass spectrometry (ESI-LC/MS) analysis. The standard curves 
for the various metabolites that were used for the quantification and determination of the 
KM and Vmaz values were generated by subjecting various known amounts of authentic 
standards to ESI-LC/MS analysis. 
ESI-LC/MS Analysis. Samples (10 µL) were injected onto a Hypersil ODS 
column (5 µm, 4.6 × 100 mm; Thermo Fisher Scientific, Waltham, MA) that was 
equilibrated with 25% solvent A (0.1% acetic acid in water) and 75% solvent B (0.1% 
acetic acid in methanol). The metabolites were resolved using the following gradient: 0 to 
5 min, 75% B; 5 to 20 min, 75 to 100% B; 20 to 25 min, 100% B; 25 to 26 min, 100 to 
75% B; and 26 to 30 min, 75% B. The flow rate was 0.3 ml/min. The column effluent 
was directed into the LCQ mass analyzer (Thermo Fisher Scientific). The ESI conditions 
were as follows: sheath gas, 90 arbitrary units; auxiliary gas, 30 arbitrary units; capillary 
temperature, 200°C; and spray voltage, 4.5 V. Data were acquired in positive ion mode 
for anandamide and its metabolites using the Xcalibur software package (Thermo Fisher 
Scientific) with one full scan from 300 to 500 mass/charge ratio (m/z) followed by one 
data-dependent scan of the most intense ion.  
Data Analysis. Nonlinear regression analyses of the data were performed using 






Human Liver S9 Metabolism of Anandamide. Before we could determine the efficacy 
of the selected sEHIs for inhibiting the hydrolysis of the EET-EAs, we had to investigate 
the metabolism of AEA by human liver S9 fractions. S9 fraction preparation was first 
described by Garner and coworkers (Garner et al., 1972). Basically, the tissue, liver in 
this situation, is homogenized and centrifuged for 10 min at 9000 g. The supernatant is 
the S9 fraction. The total ion chromatogram (TIC) and extracted ion chromatograms for 
the metabolites formed having m/z values of 364 and 382 can be seen in Figure 3.1. Six 
mono-oxygenated metabolites were detected. Two of the metabolites were hydroxylated, 
19- and 20-HETE-EA, and four were epoxygenated, 5,6-, 8,9-, 11,12-, and 14,15-EET-
EA. These were identified from their retention times and MS/MS spectra by comparison 
with authentic standards, except for 19-HETE-EA, for which an authentic standard is not 
yet available. In order to determine the kinetic data, we used assay conditions where 
product formation was linear with respect to the protein concentration and the selected 
incubation time. The kinetic data for substrate concentration vs. product formation were 
plotted for 14,15-, 11,12-, 8,9-, and 5,6-EET-EA, see Figure 3.2. Because we were unable 
to reach saturation at the concentrations of AEA used, the kinetic parameters for these 
metabolites could not be determined. The formation of 19- and 20-HETE-EAs by human 
liver S9 exhibited simple Michaelis-Menten kinetics and nonlinear regression was used to 
calculate the apparent Km and Vmax values. The Km values calculated for the formation of 
19- and 20-HETE-EA were 199 and 63 µM, respectively, and the Vmax values were 137 





  Figure 3.1. AEA metabolism by human liver S9. Liver S9 protein (0.8 mg/mL) was 
incubated with AEA (100 µM) in 100 mM potassium phosphate buffer, pH 7.4, 
containing 3.3 mM MgCl2. The reaction was started by the addition of 1.3 mM of 
NADPH and the samples were incubated at 37°C with shaking. The reaction was stopped 
with ice cold ethyl acetate after 20 min. The metabolites were extracted from the reaction 
mixture as described in Materials and Methods. The TIC shows all the ions detected by 
the LC/MS (Top). The ions observed at m/z 364 represent the mono-oxygenated 
metabolites, the HETE-EAs and the EET-EAs (Middle).The peaks observed at m/z 382 





  Figure 3.2. Kinetic data for the metabolism of AEA by human liver S9. Reaction 
mixtures containing human liver S9 (200 µg) and AEA (2.5-1000 µM) were incubated 
for 10 and 20 (20-HETE-EA only) min in 0.1 M phosphate buffer, pH 7.4, at 37°C with 
shaking. The reactions were quenched and the samples were extracted as described in 
Materials and Methods. The amount of metabolites formed was calculated based on a 
standard curve obtained for each metabolite. Since an authentic standard for 19-HETE-
EA is not available, its formation is based on the standard curve for 20-HETE-EA. The 
rate data were fitted to the Michaelis-Menten enzyme kinetic model using the Graphpad 




The Effect of AUDA on EET-EA Levels Measured in Liver S9 Incubations. 
AUDA is a potent sEHI that is commonly used to inhibit sEH-mediated hydrolysis of  
EETs in several in vitro and in vivo models (Inceoglu et al., 2006; Olearczyk et al., 2006; 
Xu et al., 2006). Due to the structural similarities between the EETs and the EET-EAs, 
we tested AUDA for its ability to inhibit the hydrolysis of the EET-EAs. Figure 3.3 
shows the extracted ion chromatograms at m/z 364 and 382 from which the relative levels 
of EET-EAs and DHET-EAs present can be determined, respectively. For the epoxide 
metabolites, increasing the concentration of AUDA generally caused the expected 
increase in the area of the respective peaks. Similarly, the peaks representative of the 
DHET-EAs decreased in area as the amount of AUDA added to the incubations 
increased. Because we were unable to accurately quantify the amount of DHET-EAs 
formed, we were unable to determine if the increase in EET-EA formation was indirectly 
proportional to the decrease in DHET-EA formation.  Interestingly, at the highest 
concentration of AUDA tested (100 µM), the peak areas decreased for all of the epoxides 
except for the 14,15-EET-EA. Since AUDA also caused a significant decrease in the 
amount of 20-HETE-EA formed, this decrease in product formation may be due to 
inhibition of P450-catalyzed metabolism of AEA to form the epoxides. 
 
Determination of the EC50 Values for AUDA, APAU, and TPPU. Because 
AUDA was able to increase the total amounts of the EET-EAs measured following liver 
S9 metabolism, we also investigated the effects on the two other sEHIs, APAU and 
TPPU on epoxide levels formed by human liver S9 using a similar approach. From these 





  Figure 3.3. Formation of EET-EAs and DHET-EAs by human liver S9 in the presence of 
AUDA. Human liver S9 protein (0.8 mg/mL) was incubated with AEA (100 µM) and 
varying concentrations of AUDA in 0.1 M phosphate buffer containing MgCl2 for 30 min 
at 37°C with shaking. The reaction was stopped and the metabolites extracted as 
previously described in Materials and Methods. The color traces represent the following 
concentrations of AUDA added: vehicle only (black), 0.1 µM (red), 1 µM (blue), 10 µM 




metabolites were investigated for AUDA, APAU, and TPPU, all of which are potent 
inhibitors of sEH and thus EET hydrolysis. All of the sEHIs used exhibited IC50 values at 
nanomolar levels for the inhibition of sEH activity (Jones et al., 2006; Morisseau et al., 
2002; Rose et al., 2010). A wide range of concentrations was initially tried for each of the 
sEHIs to determine the correct range of inhibitor concentration to perform the EC50 
evaluations for the inhibition of EET-EA hydrolysis.  
AUDA slightly increased 11,12-EET-EA levels, had no effect of 8,9-EET-EA 
levels, and decreased 5,6-EET-EA levels in a dose dependent manner (Figure 3.4A and  
B). AUDA significantly increased the formation of 14,15-EET-EA and its EC50 value 
was calculated as 5.6 ± 0.002 µM (Figure 3.4C). Although the presence of APAU 
significantly increased the formation of all four of the EET-EAs as compared to control 
(Figure 3.5A and B), EC50 values could only be calculated for 11,12- and 14,15-EET-EAs 
which were 4.7 ± 0.002 µM and 10.4 ± 0.003 µM, respectively (Figure 3.5C and D). 
Figure 3.6 shows the amount of product formed in response to increasing concentrations 
of TPPU. Although the addition of TPPU did significantly increase formation of 14,15- 
and 11,12-EET-EAs, this did not occur in a dose dependent manner. In addition, TPPU 
had no effect on the formation of 8,9- and 5,6-EET-EAs. As a result, no EC50 values 
could be obtained from the TPPU data. 
 
Discussion 
Anandamide is an endogenous cannabinoid that elicits several beneficial effects in 









Figure 3.4. EC50 determination for AUDA. Human liver S9 (200 µg) was incubated with 
AUDA (0.1 nM-400 µM) in the reaction buffer as described in Materials and Methods. 
NADPH (1.3 mM) was added to start the reactions which were incubated for 30 min 
37°C. The reactions were stopped with 1mL of ethyl acetate and extracted twice. Sample 
preparation was performed as described in Materials and Methods. The bars in (A) and 
(B) represent the mean ± SEM from one experiment performed in duplicate. Statistical 
significance was determined using the Holm-Sidak method in the Graphpad Prism 6 
program. The points plotted in (C) for 14,15-EET-EA were obtained by subtracting the 
control amount from the total amount measured. Data points without error bars represent 
individual measurements. Data points with error bars represent the mean ± SEM for one 




  Figure 3.5. EC50 determination for APAU. Human liver S9 (0.8 mg/mL) was incubated 
with APAU (1 nM-1 mM) in the reaction buffer as described in Materials and Methods. 
NADPH (1.3 mM) was added to initiate the reactions which were continued for 30 min 
37°C. The reactions were stopped and samples extracted as previously described in 
Materials and Methods. The bars in (A) and (B) represent the mean ± SEM from one 
experiment performed in duplicate. Statistical significance was determined using the 
Holm-Sidak method in the Graphpad Prism 6 program. The points plotted in (C) for 
14,15-EET-EA and (D) for 11,12-EET-EA represent the increase in product formation 
above control levels. Data points represent the mean ± SEM for one experiment 




   
  
Figure 3.6. Effect of TPPU on EET-EA levels. Human liver S9 fraction (200 µg) was 
incubated with TPPU (1 nM-250 µM) in 100 mM potassium phosphate buffer, pH 7.4. 
The reactions were initiated by the addition of NADPH (1.3 mM) and samples were 
incubated for 30 min 37°C with shaking. The reactions were quenched with 1mL of ethyl 
acetate and extracted twice. Sample preparation was performed as described in Materials 
and Methods. Although there were several treatment groups that varied significantly from 
control, these variations did not occur in a dose dependent manner and therefore the EC50 
values could not be calculated. The bars represent the mean ± SEM from one experiment 
performed in duplicate. Statistical significance was determined using the Holm-Sidak 




(Snider et al., 2010). Several P450s are known to metabolize AEA to give the 19- and 20- 
HETE-EAs and the 5,6-, 8,9-, 11,12- and 14,15-EET-EAs (Pratt-Hyatt et al., 2010; 
Snider et al., 2007; Snider et al., 2008; Sridar et al., 2011; Stark et al., 2008). The 
structure of AEA is closely related to that of AA. AA is metabolized by P450s to give 
several HETEs and 5,6-, 8,9-, 11,12- and 14,15-EET (Roman, 2002) . Soluble epoxide 
hydrolase inhibitors have been used to inhibit EET hydrolysis and study their biological 
functions in vivo (Morisseau and Hammock, 2013). As a result, we investigated the 
ability of three potent sEHIs to inhibit the hydrolysis of the EET-EAs in an effort to 
determine their usefulness in studying the biological of the EET-EAs in vivo. We chose 
to use the human liver S9 preparation as an enzyme source because it should exhibit 
higher sEH activity than microsomal preparations which should not include the cytosolic 
fraction. 
We first investigated the metabolism of AEA by human liver S9 fractions. Figure 
3.1 showed the LC/MS chromatogram of the products formed. The metabolites were the 
same as those known to be formed by human liver microsomes (HLM) (Snider et al., 
2007); however, the product profile was slightly different. With HLM, 8,9-EET-EA was 
the major product observed; however, with human liver S9, the 5,6-EET-EA was 
determined to be the major product (Snider et al., 2007). Whether this difference is due to 
the differences in the pools of the livers used for the preparation of the S9 and the 
microsomes or an intrinsic difference between S9 and microsomal metabolism is not 
clear. The S9 fraction contains microsomal and cytosolic proteins. Investigations 
completed by Slaughter and coworkers determined that microsomal incubations and 




respectively (Slaughter et al., 2003). Therefore, the presence of the cytosol in the enzyme 
source from this work as compared to previous studies may account for the observed 
differences. Moreover, the presence of multiple isoforms of epoxide hydrolases, such as 
microsomal, soluble, and potentially others, makes it difficult to definitively determine 
the kinetic parameters of these labile compounds suggesting that microsomes are a better 
enzyme source to study kinetics; however, the reaction conditions reported here are 
probably more similar to in vivo conditions than the microsomal studies with regard to 
enzymatic activity.  
It is possible that both mEH and sEH are present in the human liver S9 fraction. 
This may explain why at the concentrations of AEA used, we were unable reach 
saturation for the formation of the EET-EAs and determine Km and Vmax values. The Km 
we reported for liver S9 formation of 20-HETE-EA is about 25 times higher than the Km 
reported in HLM (Snider et al., 2007). On the other hand, our reported Vmax value was 
two times greater than that reported for HLM (Snider et al., 2007). The kinetics for 19-
HETE-EA were not reported in the previous study, so there is no comparison to be made; 
however, the liver S9 is more efficient at 20-HETE-EA formation than 19-HETE-EA 
formation based on Vmax/Km values of 8 and 0.7 pmols/min/mg of protein, respectively.  
Only the IC50 values for sEH  activity as measured using the radioactive substrate 
[
3
H]-tDPPO or the fluorescent substrate α-cyanocarbonate have been reported in the 
literature for the three sEHIs studied (Jones et al., 2006; Morisseau et al., 2002; Rose et 
al., 2010). However, one lab has reported an EC50 value for AUDA of 2 µM for 
inhibition of 14,15-EET-induced vasorelaxation of precontracted bovine coronary arteries 




AUDA inhibition of 14,15-EET-EA hydrolysis. We observed that AUDA inhibited the 
hydrolysis of the 14,15- and 11,12-EET-EAs at low micromolar levels leading to 
increased levels of epoxides, but decreases in the yields of the epoxides were observed at 
higher levels for 5,6-, 8,9-, and 11,12-EET-EAs. Increasing the AUDA concentration 
caused a continuous decrease in 5,6-EET-EA formation at all concentrations used. 
AUDA also inhibited 20-HETE-EA formation in a dose-dependent manner, but had little 
to no effect on the formation of 19-HETE-EA (Figure 3.3). AUDA is rapidly metabolized 
in vivo, and its adamantine group is sensitive to P450-catalyzed oxidation (Morisseau and 
Hammock, 2013). Thus, the decreases in the EET-EA levels and 20-HETE-EA formation 
at higher concentrations of AUDA may be due to competitive inhibition of the P450s 
responsible for their formation by AUDA. It is unlikely that either APAU or TPPU are 
inhibitors of P450 activity since their presence did not significantly affect 20-HETE-EA 
formation (data not shown). 
APAU caused an increase in the levels of all of the EET-EAs, but EC50 values 
could only be calculated for the 14,15- and 11,12-EET-EAs. TPPU caused significant 
increases in the epoxide levels at the highest concentration tested for 11,12- and 14,15-
EET-EA, but the  inhibition data were not consistent enough to calculate an EC50 value. 
TPPU had a relatively minor effect on 8,9-EET-EA levels and no effect on 5,6-EET-EA 
hydrolysis. The various degrees of inhibition exhibited by the sEHIs for the hydrolysis of 
each of the EET-EAs suggest that the substrate preference of sEH for these metabolites 
may be similar to that for the EETs with 14,15-EET-EA being the preferred substrate, 




In conclusion, humans have several different EHs (Decker et al., 2009; Morisseau 
and Hammock, 2013), and it is likely that at least two of the major forms, mEH and sEH, 
are present in the liver S9 fraction used as an enzyme source for these studies. It is known 
that potent inhibitors of sEH such as AUDA, APAU, and TPPU do not inhibit mEH 
activity and vice versa, inhibitors of mEH do not inhibit sEH (Morisseau et al., 2008; 
Shen and Hammock, 2012).  The presence of at least two isoforms of EHs in the S9 
fraction and the use of inhibitors specific for only one isoform may be responsible for the 
differences observed in the inhibition, or lack thereof for the four different EET-EAs. 
There may be differences in selectivity for each of the EET-EAs when observing mEH 
activity vs. sEH activity. Future studies investigating the specific EHs (soluble or 
microsomal) responsible for the hydrolysis of each of the EET-EAs and the development 
of compounds more specific and potent for the inhibition of the EHs responsible for the 
hydrolysis of the EET-EAs will be required in order to have a better chance of 
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Metabolism of the Synthetic Cannabinoid JWH-018 and Its Effect on Heart Rate 
and Blood Pressure in Rats 
 
Abstract 
The marijuana substitute, “Spice” or “K2”, is a significant drug of abuse in the 
United States and abroad. The side effects observed from using this product range from 
mild to deadly. JWH-018 is one of the main synthetic cannabinoids (SCs) that acts as the 
active ingredient in Spice products. It is important to understand the metabolism of this 
drug in the body to determine if the parent and/or an active metabolite cause the observed 
toxicities. This information may aid in the discovery of a treatment for toxicity due to this 
and similar compounds. Although several cytochrome P450s have been investigated for 
their ability to metabolize JWH-018, CYP2J2, a P450 primarily expressed in the heart 
which is a critical target organ for JWH-018 toxicity, has not been studied in detail. In the 
reconstituted system, CYP2J2 metabolizes JWH-018 mostly to give the JWH-018 ω-1-
OH metabolite with an observed KM of 10 µM and a kcat value of 0.2 pmol/min/pmol of 
P450. These kinetic parameters are comparable to those for CYP2C9, which is believed 
to contribute significantly to JWH-018 metabolism in the liver; however, CYP2J2 is not 
as efficient as CYP2C9 at the metabolism of JWH-018. In addition, the metabolism of 
JWH-018 was studied in human intestinal and liver microsomes and in an animal model. 




dihydroxydiol metabolite which could not be identified unequivocally. This product was 
formed by all of the human and rat organ tissues examined. Animal studies suggest that 
JWH-018 does not affect heart rate, but it does cause a significant increase in blood 
pressure. Future studies are needed to determine the efficacy of the major metabolic 
products of JWH-018 in vivo, especially the dihydroxydiol product, since several JWH-
018 metabolites are known to retain biological activity. 
 
Introduction 
Cannabis or marijuana has been used medically and recreationally for thousands 
of years (Mechoulam and Hanus, 2000; Robson, 2005). Generally, SCs are based on the 





-THC). The therapeutic potential of cannabinoid-based compounds did not become 
evident until after the cloning of the two cannabinoid receptors (Matsuda et al., 1990; 
Munro et al., 1993). Both receptors are primarily associated with G-proteins of the Gαi 
and Gαo families, and as a result, their activation leads to inhibition of cAMP 
accumulation in cells (Howlett, 2005; Pertwee, 2005); however, coupling of the receptors 
to other G-proteins has been reported as well (Glass and Felder, 1997; Lauckner et al., 
2005). Cannabinoid 1 receptors (CB1Rs) are abundantly expressed in the brain, but are 
also present in peripheral tissues such as the heart and lungs at much lower levels 
(Galiegue et al., 1995). The cannabinoid 2 receptor (CB2R) is mostly expressed in the 
immune system (Galiegue et al., 1995).  In order to study the cannabinoid system, Dr. 




(see Figure 4.1), is found in almost all of the K2 products currently available (Atwood et 
al., 2010; Huffman et al., 1994; Wiley et al., 1998). 
Since 2004, K2 products have been marketed legally as natural herbal incense at 
convenience stores, gas stations, and via the Internet. As a result, many users believe that 
the products are “safe” because of easy availability and lack of government regulation 
(Every-Palmer, 2011).  However, in 2011, the Drug Enforcement Administration placed 
five SCs, including JWH-018,  into Schedule I of the Controlled Substances Act (Pant et 
al., 2012). K2 products usually contain non-psychoactive plant matter which has been 
altered by the addition of various SCs (Atwood et al., 2010; Hudson et al., 2010; 
Uchiyama et al., 2010; Zuba et al., 2011). These products are believed to be popular, 
especially among teenagers and young adults, due to their potent psychoactivity, 
availability, and lack of detection in commonly used drug tests (Every-Palmer, 2011). 
Unlike SC-containing products such as K2, marijuana contains over 60 
cannabinoids that modulate the effects of ∆
9
-THC (Pertwee, 2008). The synthetic 
cannabinoids present in K2 products have a higher affinity and greater efficacy at CB1Rs 
than ∆
9
-THC, which increases the chance of toxicity (Gunderson et al., 2012). Moreover, 
metabolites of synthetic cannabinoids are known to bind to and activate the CB1R, more 
so than ∆
9
-THC, which makes toxicity more likely after K2 usage (Brents et al., 2011; 
Chimalakonda et al., 2012). Moreover, studies utilizing monkeys revealed that SCs such 
as JWH-018 have a short duration of action which may lead to more frequent usage 
(Ginsburg et al., 2012). The relatively short duration time for their effects combined with 
increased potency at CB1Rs could lead to a greater risk for dependence (Ginsburg et al., 








CB2R with a Ki of 2.9 nM which is comparable to its affinity at the CB1R (Aung et al., 
2000). Since little is known about the pharmacology and toxicity of JWH-018 and its 
metabolites in humans, research is needed to investigate the metabolism of JWH-018 and 
the effects of it and its pharmacologically active metabolites in the body.  
JWH-018 undergoes extensive cytochrome P450-mediated phase I metabolism 
and redistribution into body fat (Poklis et al., 2012). Cytochrome P450s or CYPs are a 
superfamily of mono-oxygenases involved in the metabolism of a wide variety of 
endogenous and exogenous compounds (Ortiz de Montellano, 2005). Oxidized CYP 
metabolites can be subsequently glucuronidated by UDP-glucuronosyltransferases (Seely 
et al., 2012), as a result, the majority of JWH-018 metabolites are excreted as 
glucuronides in human urine (Chimalakonda et al., 2011a; Chimalakonda et al., 2011b), 
including the three major  metabolites of JWH-018: the ω-OH, ω-1-OH, and ω-COOH 
(Chimalakonda et al., 2011b; ElSohly et al., 2011; Lapoint et al., 2011; Moran et al., 
2011). 
 Using human liver microsomes, Chimalakonda and coworkers determined that 
CYP2C9 is responsible for the formation of the ω-OH and ω-1-OH metabolites of JWH-
018, whereas CYP1A2 is responsible for the formation of the carboxylated metabolite 
(Chimalakonda et al., 2012). CYP2J2 is a P450 epoxygenase mainly expressed in the 
cardiovascular system, but it is also expressed in the intestines, lung, kidney, liver, brain, 
salivary ducts, stomach, and vascular smooth muscle cells (Enayetallah et al., 2004). Due 
to the cardiovascular side effects observed after exposure to JWH-018 in K2 products, the 
ability of the major cardiovascular P450, CYP2J2, to metabolize JWH-018 was 




to observe the metabolism of JWH-018 and its effects on heart rate and blood pressure. 
JWH-018 is normally administered via inhalation so that the lungs and heart are the first 
two organs to be exposed to the compound; however, there are some reports describing 
JWH-018 ingestion. In this situation, JWH-018 undergoes first pass metabolism by the 
intestine and liver. JWH-018 can be metabolized in the intestine and the metabolites and 
the remaining JWH-018 are absorbed into the portal vein and travel to the liver where 
additional metabolism occurs. After the remaining JWH-018 and its metabolites leave the 
liver, these compounds enter systemic circulation and can potentially cause several 
physiological effects, including those related to the cardiovascular system. As a result, 
the metabolism of JWH-018 by human intestine and liver microsomes was also 
investigated to determine the metabolite profiles.  
 
Materials and Methods 
Materials. AM251, ω-OH and ω-1-OH JWH-018 were purchased from Cayman 
Chemical (Ann Arbor, MI). JWH-018 was purchased from Ark Pharm, Inc. (Libertyville, 
IL). Rat hearts and livers were gifts from the lab of Dr. Margaret Gnegy (University of 
Michigan, Ann Arbor, MI). All other reagents were of the highest quality and were 
obtained from commercial sources. 
Enzymes. The human CYP450 CYP2J2 cDNA was a gift from Dr. Rheem Totah 
(University of Washington, Seattle, WA). CYP2J2 and CYP450 reductase were 
expressed in Escherichia coli and purified as previously described (Hanna et al., 1998; 
Smith et al., 2008). Human intestine (Lot #s: 3077535; 05866) and liver (Lot #: 88114) 




Preparation of Microsomes from Rat Hearts and Livers. The preparation of 
microsomes was performed as described previously (Lin et al., 1998). Briefly, the hearts 
or livers of three Sprague Dawley rats were pooled, chopped, and subsequently 
homogenized using a Tissue Tearor (Biospec Product Inc.) in homogenization buffer 
(100 mM potassium phosphate buffer, pH 7.4, 1 mM EDTA, and 150 mM KCl). The 
homogenate was centrifuged at 10,000 g for 30 min and the supernatant was filtered 
through gauze to remove the fat. The supernatant was ultracentrifuged at 100,000 g for 75 
min. The resulting pellet was resuspended using a glass pestle in a Dounce homogenizer 
in pyrophosphate buffer (100 mM tetrasodium pyrophosphate, pH 7.4 and 1 mM EDTA) 
to remove hemoglobin. The homogenate was centrifuged again at 100,000 g for 75 min 
and the resulting pellet was resuspended in suspension buffer (100 mM potassium 
phosphate buffer, pH 7.4, 1 mM EDTA, and 20% glycerol). Bovine serum albumin was 
used as the standard for the BCA Protein Assay (Pierce, Rockford, IL) which was used to 
determine the protein concentrations of the microsomes. 
JWH-018 Metabolism Assays. Recombinant Protein. CYP2J2 was reconstituted 
with reductase (1:2) and L-α-dilauroyl-phosphocholine (DLPC) lipid on ice for 60 min as 
described previously (Snider et al., 2007; von Weymarn et al., 2004). The metabolism of 
JWH-018 was determined using incubation mixtures (0.25 mL) containing 100 mM 
potassium phosphate buffer (pH 7.4), catalase (22 µg), JWH-018 (5-50 µM), and 
reconstituted CYP2J2. The reactions were initiated by the addition of 1.2 mM of NADPH 
and allowed to continue for 15 min at 37°C.  
Microsomal JWH-018 Metabolism Studies. Human intestinal microsomes (HIM), 




(RLM) (0.8 mg/mL) were combined with 100 mM potassium phosphate buffer, pH 7.4, 
3.3 mM MgCl2 and 100 µM JWH-018 in a final volume of 250 µL. The reactions were 
initiated by the addition of 1.3 mM NADPH and allowed to continue for 20 (RLM), 30 
(HIM and HLM), and 45 (RHM) min. Control reactions were performed in the absence of 
NADPH. Product formation was linear with respect to time and protein concentration 
under these conditions. 
All reactions were terminated by the addition of 1 ml of ice cold ethyl acetate. 
After the addition of the internal standard, JWH-018-d9, the samples were vortexed 
briefly and centrifuged at full speed using a desktop Eppendorf centrifuge for 15 min. 
The organic layer was dried down under a constant stream of nitrogen gas. The dried 
samples were resuspended in 100 µL of 50% acetonitrile and subjected to electrospray 
ionization-liquid chromatography/mass spectrometry (ESI-LC/MS) analysis. The 
standard curves for the metabolites used for the quantification and the determination of 
the KM and kcat values were determined by injecting various known amounts of authentic 
standards into the ESI-LC/MS for analysis. 
ESI-LC/MS Analysis. Samples (10 µL) were injected onto a ZORBAX Eclipse 
XDB-C18 column (3.5 µm, 3 × 150 mm; Agilent Technologies, Santa Clara, CA) that 
was equilibrated with 50% solvent A (0.1% formic acid in water) and 50% solvent B 
(0.1% formic acid in acetonitrile). The metabolites were resolved using the following 
gradient: 0 to 20 min, 50% B; 20 to 21 min, 50 to 95% B; 21 to 35 min, 95% B. The flow 
rate was 0.3 ml/min. The column effluent was directed into the LCQ mass analyzer 
(Thermo Fisher Scientific). The ESI conditions were as follows: sheath gas, 90 arbitrary 




4.5 V. Data were acquired in positive ion mode for JWH-018 and its metabolites using 
the Xcalibur software package (Thermo Fisher Scientific) with one full scan from 300 to 
500 mass/charge ratio (m/z) followed by one data-dependent scan of the most intense ion.  
Animal Studies. Animals. Sprague-Dawley rats purchased from Harlan, Inc. 
(Indianapolis, IN) were housed in groups with a continuous availability of food and 
water. Housing and experimental rooms functioned on a 12 hr light/dark cycle at 21°C. 
The protocols used were approved by the University of Michigan University Committee 
on the Use and Care of Animals and satisfied the guidelines set forth by the NIH Guide 
for the Use of Laboratory Animals. 
Surgical Procedures. The rats were fitted with telemetric transmitters (TA11PA-
C40 or TL11M2-C50-PXT, Data Sciences International, Transoma Medical Inc., St. Paul, 
MN) using the anesthetics ketamine (90 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.) in 
order to measure heart rate (HR) and mean arterial pressure (MAP) as previously 
described (Jutkiewicz et al., 2013). Briefly, the monitoring system consisted of implanted 
battery-operated transmitters, Physiotel receivers, the DSI Data Exchange Matrix, and the 
Dataquest A.R.T. system. The data collected by the receiver were stored on a computer. 
The transmitter was placed in a subcutaneous pocket between the skin and muscle on the 
abdominal side. A suture secured the subcutaneous catheter that extended from the base 
of the transmitter into the femoral artery 2-3 cm. The rats were allowed to recover at least 
seven days prior to experimentation. 
Experimental Design. The caged rats were placed on top of the receivers and 
baseline data were recorded for at least one hour prior to the experiment to allow heart 




the intraperitoneal (i.p.) injections and handling procedures used for these experiments, 
all rats were given a saline injection at least 30 min prior to the start of the experiment. 
All doses were administered i.p. in a volume of 1 mL/kg. 
Data Analysis. The heart rate and blood pressure data were calculated using the 
Dataquest A.R.T. Gold Analysis 3.01 software. This program averaged the heart rate 
(HR) and mean arterial pressure (MAP) values for every 10 s. Those values were 
subsequently averaged for every minute. Individual rat data were then calculated as the 
percent change from resting HR or MAP. Nonlinear regression, two-way ANOVA, and 
unpaired t test with Welch’s correction of the data were performed using GraphPad Prism 
6 (GraphPad Software Inc., San Diego, CA; http://www.graphpad.com). 
 
Results 
Metabolism of JWH-018 by Human Recombinant CYP2J2. JWH-018 
undergoes an extensive cytochrome P450-mediated phase I metabolism and redistribution 
into body fat (Poklis et al., 2012). Utilizing recombinant human proteins and human liver 
microsomes, Chimalakonda and others determined that CYP2C9 is primarily responsible 
for the formation of the ω-OH JWH-018 and ω-1-OH JWH-018 metabolite whereas, 
CYP1A2 is responsible for the formation of the carboxylated metabolite (Chimalakonda 
et al., 2012). CYP2J2 is a P450 epoxygenase mainly expressed in the cardiovascular 
system, but it is also expressed in the intestines, lung, kidney, liver, brain, salivary ducts, 
stomach, and vascular smooth muscle cells (Enayetallah et al., 2004). Due to the very 




products, we investigated the ability of the major cardiovascular P450, CYP2J2, to 
metabolize JWH-018. 
Figure 4.2 shows the ESI-LC/MS chromatogram for the metabolism of JWH-018 
by purified human CYP2J2. The extracted ion chromatogram at m/z 358 at the bottom of 
the figure shows the two mono-oxygenated metabolites formed during JWH-018 
metabolism by CYP2J2. Although several different mass-to-charge ratios were monitored 
including m/z 358, 374, and 390, only the two mono-oxygenated products were observed. 
At m/z 358, the N-(5-hydroxypentyl) (ω-OH) and the N-(4-hydroxypentyl) (ω-1-OH)  
metabolites of JWH-018 eluted after approximately 23 and 24 min, respectively. These 
were the only products observed for CYP2J2-catalyzed oxidation of JWH-018. The 
identities of the products were confirmed based on retention times and fragmentation 
patterns of commercially available standards (data not shown). Of the two products 
formed, the JWH-018 ω-1-OH metabolite was the major product formed. 
Kinetic Studies on the Metabolism of JWH-018 by Human Recombinant 
CYP2J2. Although the metabolism of JWH-018 was previously shown by the lab of Dr. 
Jeffrey Moran (poster), this is the first investigation regarding the kinetics of this 
reaction. To determine the ability of CYP2J2 to metabolize JWH-018, the kinetic 
parameters, KM and kcat, were determined for the two hydroxylated products. The 
CYP2J2-catalyzed formation of the ω-OH and ω-1-OH products was linear with both the 
protein concentration and time used to determine the kinetic constants (data not shown). 
As shown in Figure 4.3, the formation of the JWH-018 ω-OH and ω-1-OH metabolites 
exhibited typical Michaelis-Menten kinetics with observed KM values of 11 and 10 µM 




  Figure 4.2. JWH-018 metabolism by recombinant CYP2J2. Purified CYP2J2 was 
reconstituted with reductase (1:2 ratio) in lipid (L-α-dilauroyl-phosphocholine) on ice for 
at least 60 min. This enzyme source (9 µL) was added to the incubation mixture (0.25 
mL) containing 100 mM potassium phosphate buffer (pH 7.4), JWH-018 (50 µM), and 
catalase. Reactions were initiated by the addition of 1.2 mM NADPH and allowed to 
continue for 15 min at 37°C. The total ion chromatogram (TIC) shows the all the ions 
captured by the LC/MS (Top). The middle chromatogram shows the positive ion formed 
by the parent compound, JWH-018, at m/z 342 which eluted after 29.8 min. The extracted 
ion chromatogram observed at m/z 358, shows the monooxygenated product peaks which 
elute at approximately 23.2 and 24.4 min for JWH-018 ω-OH and JWH-018 ω-1-OH, 
respectively. The product identities were verified by comparing the retention times and 






 Figure 4.3. Kinetics for JWH-018 metabolism by purified CYP2J2. Several 
concentrations of JWH-018 (5-50 µM) were metabolized by purified CYP2J2 for 
15 min at 37°C, as described in Materials and Methods. To determine the amount 
of product formed, a standard curve was constructed for the metabolites using 
commercially available standards. The two mono-oxygenated products formed 
were ω-1-OH (●) and ω-OH JWH-018 (∎). The data are the average of three 










The Effect of JWH-018 on Heart Rate and Blood Pressure in Rats. When the 
heart rate (HR) and mean arterial pressure (MAP) returned to resting levels after a control 
saline injection, the rats were injected with either vehicle (1:1:3-ethanol:alkamuls-
EL620:sterile water) or the CB1R antagonist AM251 (10 mg/kg) as a pretreatment. After 
30 min, the rats in those two groups were then injected with the vehicle or JWH-018 (3 
mg/kg). The HRs and MAPs of these rats were monitored for three hours after the 
treatment dose. Figure 4.4 shows the data collected by telemetry in five minute intervals 
for the HR (Figure 4.4A) and the MAP (Figure 4.4B). Although JWH-018 seemed to 
have little to no effect on HR, it did cause a significant increase in the MAP. Pretreatment 
with AM251, the CB1R antagonist, partially blocked the increase in blood pressure 
caused by administration of JWH-018. However, about 20 min into the 30 min 
pretreatment, the HRs and MAPs of the rats returned to resting levels for the vehicle 
injected rats, but the HRs and MAPs for the rats pretreated with AM251 never decreased 
and were significantly different from vehicle-treated rats (data not shown). Inhibition of 
presynaptic CB1R in the cardiovascular system cause the release of neurotransmitters 
which subsequently increase heart rate and blood pressure. 
Substrate Competition Between JWH-018 and Arachidonic Acid. CYP2J2 
metabolizes arachidonic acid (AA) to yield four epoxides that have been shown to 
participate in the regulation of cardiovascular homeostasis (Roman, 2002). Since JWH-
018 is also a substrate for CYP2J2, it is possible that JWH-018 interferes with AA 




  Figure 4.4. The effect of JWH-018 on heart rate and blood pressure in rats. Sprague-
Dawley rats were given an intraperitoneal (i.p.) pretreatment injection of either vehicle or 
the CB1R antagonist, AM251 (10 mg/kg). After 30 min, the rats were administered an 
i.p. injection of vehicle (vehicle + vehicle, ○, n= 6); or 3 mg/kg dose of JWH-018 
(vehicle + JWH-018, □, n= 6); or (AM251 + JWH-018, ∎, n= 5). The HRs (A) and 
MAPs (B) of the rats were monitored via an implanted telemetry device as described in 
Materials and Methods. The values plotted on the graph represent mean ± SEM for all of 
the rats in each of the indicated test groups. Statistical significance was determined using 
the Holm-Sidak method. *, vehicle + vehicle vs. vehicle + JWH-018; #, vehicle + vehicle 
vs. AM251 + JWH-018; †, vehicle + JWH-018 vs. AM251 + JWH-018. #, P < 0.05; ##, P 




  Figure 4.5. Competition between JWH-018 and AA for metabolism by CYP2J2. 
Recombinant CYP2J2 was reconstituted with reductase (1:2 ratio) and DLPC for 60 
min on ice. AA (20 µM) was combined with JWH-018 (0, 10, 20, and 40 µM) for 30 
min at 37°C, as described in Materials and Methods. The metabolites formed are: 
14,15-EET (●); 11,12-EET (∎); 8,9-EET (▲); 5,6-EET (▼). The data are the 
average of two separate experiments done in duplicate and the error bars represent 




shows the effect of JWH-018 on the metabolism of AA by CYP2J2. Surprisingly, rather 
than causing inhibition of the metabolism of AA, the presence of JWH-018 significantly 
increased the production of three of the four epoxide metabolites, the 14,15-, 11,12-, and 
8,9-EETs. It also caused a slight increase in the formation of 5,6-EET, but this increase 
only reached significant levels when there were equal amounts of JWH-018 and AA. The 
presence of AA had no effect on JWH-018 metabolism (data not shown). 
The Metabolism of JWH-018 by Rat Heart and Liver Microsomes. In order to 
better understand the in vivo effects of JWH-018, the metabolism of JWH-018 was 
investigated utilizing rat heart and liver microsomes. Pooled heart and liver microsomes 
were prepared as described in Materials and Methods and used for metabolism studies of 
JWH-018. Several different extracted ion chromatograms were used for the analysis, 
including those at m/z 358, 374, and 390 corresponding to the mono-, di-, and trihydroxy 
metabolites, respectively. The mass-to-charge ratio that corresponds to the terminal 
carboxylated metabolite, m/z 372, was monitored as well. Figure 4.6 shows the total ion 
chromatogram (TIC) and the three different extracted ion chromatograms (m/z 338, 358, 
and 376) for the products formed by rat heart microsomes (RHM). Figure 4.7 shows the 
TIC and the extracted ion chromatograms for the products peaks at m/z values of 358, 
372, 374, 376, and 392 formed by rat liver microsomes (RLM). RHM and RLM both 
formed products that were unique to their respective tissues, but some metabolites such as 
M4, M5, M6, M8, and M9 were formed by both heart and liver microsomes. The 
monohydroxylated metabolites were the major products formed by both RHM and RLM. 
The peak observed at m/z 338 (M3) was a major product formed by RHM; however, its 




  Figure 4.6. JWH-018 metabolism by rat heart microsomes. Rat heart microsomal protein 
(0.8 mg/mL) was combined with JWH-018 (100 µM) in 0.1 M phosphate buffer 
containing MgCl2. After the addition of NADPH (1.3 mM) the reaction was incubated for 
45 min at 37°C with shaking. The reaction was terminated and the samples were prepared 
as described in Materials and Methods. Based on previous studies, the metabolite M3 is 
probably a 1,2-diol formed by the addition of two hydroxyl groups with the loss of the 
carbon chain, see Figure 4.8 (Zhang et al., 2006). While the identity of M4 is unknown, 
M5-M7 probably corresponds to hydroxyl substitutions on the indole ring of JWH-018. 






Figure 4.7. JWH-018 metabolism by rat liver microsomes. Rat liver microsomal protein 
(0.8 mg/mL) was incubated with JWH-018 (100 µM) for 20 min at 37°C under the 
standard reaction conditions stated previously in Materials and Methods. The reaction 
was performed and the metabolites were extracted as previously described in Materials 
and Methods. About 22 different metabolites of JWH-018 were formed by RLM. Three 
monohydroxylated (m/z 358) and nine dihydroxylated (m/z 374) products were formed. 
The products observed at m/z 376 are 1,2-diols and the peaks observed at m/z 392 are 1,2-
diols with an additional hydroxyl group on the indole ring or the carbon side chain 





observed at m/z 376 (M9 and M10), were formed by both RHM and RLM. These 
metabolites were minor products with RHM whereas with RLM the amount of these 
products formed corresponded to a major portion of the total metabolites produced. 
Postulated structures for these unidentified products are shown in Figure 4.8.  
 JWH-018 Metabolism by Human Liver Microsomes and Human Intestine 
Microsomes. In order to better understand any possible correlations with respect to 
JWH-018 metabolism between rats and humans, human liver microsomes (HLM) were 
also used to compare the product profiles to those seen in RLM. Metabolites formed in 
the intestine can be absorbed by the intestinal wall and enter the systemic circulation via 
the portal vein (Gao et al., 2013). This may be why JWH-018 is known to cause severe 
toxicities after ingestion (Lapoint et al., 2011). As a result, JWH-018 metabolism by 
human intestinal microsomes (HIM) was investigated as well. Because of the large 
amount of diols formed by RHM and RLM, metabolites with m/z values at 376 were 
monitored for product peak formation. Figure 4.9 shows the chromatograms for the 
products formed by HLM metabolism of JWH-018 and Figure 4.10 shows the 
chromatograms for ESI-LC/MS analysis of the metabolism of JWH-018 by HIM. In 
addition, the product profiles for the HIM and the HLM were different, the intestinal 
microsomes catalyzed less product formation from JWH-018 when compared to the liver 
microsomes when normalized for the amount of the microsomal proteins used for the 
reactions, but this decrease in activity is in accordance with other reports (Chhabra et al. 
1974).  
Human Recombinant CYP2C9 Metabolism of JWH-018. Due to its expression 




  Figure 4.8. Postulated structures for the metabolites formed from JWH-018. The top row 
shows the structures of the parent compound JWH-018 along with potential sites for 
oxygenation. The M4 product is mono-oxygenated and could have a hydroxyl group at 
any of the suggested positions except for on the indole ring or at the ω and ω-1 positions 
of the carbon chain because these products have already been identified. The M11-M19 
products are di-oxygenated and can have hydroxyl groups at any combination of two 
hydroxylation sites. The middle row shows the mono-oxygenated metabolites with 
confirmed structural identities for ω-OH and ω-1-OH JWH-018 metabolites. The other 
confirmed structures are the 5-, 6-, and 7-OH indole JWH-018 metabolites corresponding 
to M6, M5, and M7, respectively. The bottom row shows the hypothesized structures and 
potential hydroxylation sites for the products containing 1,2-diols (M3, M8-M10, and 
M20-M28). Although there are four potential sites for epoxide formation and subsequent 
hydrolysis to diols, only three products were identified, M8, M9, and M10. The three 
likely positions for the 1,2-diols are shown in box. Diol formation at the fourth potential 
position is probably limited by steric effects (adapted from Wintermeyer et al., 2010; 





  Figure 4.9. JWH-018 metabolism by human liver microsomes. To determine the 
products formed by the metabolism of JWH-018 by the liver, HLM protein (80 µg) was 
incubated with JWH-018 (20 µM) in phosphate buffer, pH 7.4. After the addition of 
NADPH, the reaction was incubated with shaking for 30 min at 37°C. The reaction was 
stopped with ethyl acetate, extracted and prepared for LC/MS analysis as stated in 
Materials and Methods. The ω-OH and the ω-1-OH metabolite eluted after 17.4 and 18.6 
min, respectively at m/z 358. Other metabolites observed at m/z 358 are the unidentified 
M4 (25.3 min) and some unresolved peaks designated as M5 and M6 that eluted after 26 
min, most likely corresponding to the JWH-018 6- and 5-hydroxyindole metabolites, 
respectively, based on the elution times of commercial standards. At m/z 374, there were 
two peaks representative of a metabolite with two separate hydroxylation sites, M12 (6 
min) and M14 (8.4 min). The extracted ion chromatogram at m/z 376 contained the major 





Figure 4.10. JWH-018 metabolism by human intestine microsomes. To identify the 
metabolites formed byJWH-018 metabolism in the intestine, HIM protein (200 µg) was 
incubated with JWH-018 (100 µM) in 100 mM of phosphate buffer, pH 7.4. NADPH was 
added and the reaction was incubated for 30 min at 37°C with shaking. The samples were 
prepared for ESI-LC/MS as previously described in Materials and Methods. The 
extracted ion chromatogram for products with m/z 358 exhibited several metabolite 
peaks: the ω-OH metabolite (21 min), M4 (25 min), and a jagged mass of peaks M5 and 
M6 that are representative of 6- and 5-hydroxylation on the indole ring of JWH-018 (c. 
26 min), respectively. At m/z 376, M8 (17 min) and M9 (21 min), the 1,2-diols were the 
major metabolites formed. The metabolites M20 (3 min) and M28 (14 min) observed at 




previously reported to be one of the major P450s involved in JWH-018 metabolism in the 
liver (Chimalakonda et al., 2012). As a result, its ability to catalyze the metabolism of 
JWH-018 was investigated and its efficiency was compared to that of CYP2J2. The ESI-
LC/MS chromatograms of the products formed (Figure 4.11) showed that CYP2C9-
mediated metabolism of JWH-018 produced four products. Three products are seen in the 
extracted ion chromatogram at m/z 358 representing the ω-OH and ω-1-OH metabolites 
of JWH-018 which eluted after approximately 23 and 24 min, respectively,  and a third 
peak eluting at about 27 min possibly corresponding to M4 or a hydroxylation on the 
indole ring. Different from CYP2J2 metabolism, the major product formed by CYP2C9-
catalyzed metabolism of JWH-018 was the ω-OH metabolite. Moreover, recombinant 
CYP2C9 also catalyzed the formation of M8 which has an m/z of 376 and eluted after 19 
min, but metabolites M9 and M10 were not formed. 
The Michaelis-Menton kinetic curves for the formation of the ω-OH and ω-1-OH 
metabolites of JWH-018 by CYP2C9 can be seen in Figure 4.12. The KM, kcat, and 
kcat/KM values for CYP2C9 metabolism of JWH-018 were calculated form these data and 
are presented in Table 4.1. The data for CYP2J2 are also provided for comparison. It can 
be seen that CYP2C9 is better at metabolizing JWH-018 than CYP2J2. 
 
Discussion 
The use of K2 has been linked to numerous deaths and emergency room visits in 
the United States alone (Lapoint et al., 2011; Pant et al., 2012; Simmons et al., 2011a; 




  Figure 4.11. JWH-018 metabolism by recombinant CYP2C9. Purified CYP2C9 was 
reconstituted with reductase and cytochrome b5 (1:2:1 ratio) in lipid (L-α-dilauroyl-
phosphocholine) on ice for at least 30 min. This enzyme source (9 µL) was then added to 
the incubation mixture (0.25 mL) containing 100 mM potassium phosphate buffer (pH 
7.4), JWH-018 (25 µM), and catalase. The reaction was initiated by the addition of 1.2 
mM of NADPH and allowed to continue for 15 min at 37°C. The reaction was stopped 
and sample extraction performed as described in Materials and Methods. The second 
chromatogram shows the parent ion which eluted after 29.8 min at m/z 342. The extracted 
ion chromatogram observed at m/z 358 shows monooxygenated product peaks which 
elute at approximately 23.7, 24.9, and 27.4 min corresponding to JWH-018 ω-OH, JWH-
018 ω-1-OH, and an unknown metabolite, respectively. An additional unknown resolved 
diol metabolite (M8) eluted after 19.2 min with an m/z values of 376, see Figure 4.8 for 
potential structure. Product identity was verified by comparing the retention times and 







Figure 4.12. Kinetic analysis for the metabolism of JWH-018 by purified 
CYP2C9. Varying amounts of JWH-018 (1-25 µM) were added to the reaction 
mixtures containing rCYP2C9 (25 pmol) and the standard reagents required for 
the reconstitution mixture. After adding NADPH, the reaction mixture was 
incubated for 15 min at 37°C with shaking. The reaction conditions and sample 
preparation were performed as described in Materials and Methods. The graph 
shows the kinetic curves for the ω-1-OH (●) and ω-OH (∎) JWH-018 metabolites. 






Table 4.1. . Comparison of Kinetic Constants for CYP2J2 and CYP2C9. Kinetic parameters 
were calculated from the data in Figures 4.3 (CYP2J2) and 4.12 (CYP2C9). Numerical values 
represent the mean ± SEM (CYP2J2, n = 9; CYP2C9, n = 3). Data for CYP1A2, CYP2C19, 




drug of abuse in the U.S. (Ginsburg et al., 2012; Gunderson et al., 2012; Seely et al., 
2011), it is important to study the metabolism of this drug in order to understand the 
metabolism and toxicology of this compound. Most reports indicate that inhalation of 
SCs produce side effects similar to marijuana including an alteration in mood, increased 
pulse rate, dry mouth and red eyes to name a few (Auwarter et al., 2009; Pant et al., 
2012). Some adverse side effects associated with SC usage that are atypical for marijuana 
usage include hypertension, nausea, vomiting, and hyperventilation (Auwarter et al., 
2009; Gunderson et al., 2012; Pant et al., 2012). Serious central nervous system effects 
include loss of consciousness, confusion, agitation, seizures, and psychosis (Every-
Palmer, 2011; Peglow et al., 2012; Simmons et al., 2011a; Simmons et al., 2011b). One 
suicide has been reported due to intolerable anxiety after K2 ingestion (Pant et al., 2012). 
Cardiovascular effects associated with synthetic cannabinoid toxicity include 
supraventricular tachycardia and myocardial infarction (Mir et al., 2011; Simmons et al., 
2011a). 
Several JWH-018 metabolites have been shown to retain their affinities and 
activities for the cannabinoid receptors in vitro and in vivo. (Brents et al., 2011; 
Chimalakonda et al., 2012; Rajasekaran et al., 2013). While the parent compound, JWH-
018, is an extremely potent agonist at the CB1R (Ki = 1.3 nM), its ω-OH and ω-1-OH 
metabolites also have good affinities at this receptor with Ki values of 35 nM and 15.4 
nM, respectively (Chimalakonda et al., 2012). In addition, all three compounds induce G-
protein activation with equal or greater efficacy than ∆
9
-THC (Brents et al., 2011; 
Chimalakonda et al., 2012). Rajasekaran and associates studied the affinity of 4-, 5-, and 




COOH), and the ω-OH and the ω-1-OH JWH-018 metabolites for the CB2R 
(Rajasekaran et al., 2013). They reported that all of the metabolites, with the exception of 
the carboxylic acid, bind to the CB2R with Ki values ranging from 20 to 115 nM 
(Rajasekaran et al., 2013). Moreover, these metabolites showed activities ranging from 
partial to full agonists for the CB2R because they activate associated G-proteins and 
inhibit adenylyl cyclase activity (Rajasekaran et al., 2013). Due to the organ specific 
expression of the cannabinoid receptors and the ability of the parent and its mono-
oxygenated metabolites to activate both cannabinoid receptors, it is important to 
investigate the metabolism of JWH-018 in tissues that exhibit high expression of a 
particular CYP compared to other P450s. CYP2J2 is the most abundant P450 in the 
human heart (Michaud et al., 2010; Wu et al., 1996). It is likely that the main route of 
JWH-018 administration is inhalation of smoke. As a result, it would not undergo 
traditional first pass metabolism in the intestine and liver, but would enter the circulation 
through the lungs and then circulate to the heart. Michaud et al. (2010) reported that 
cardiomyocytes can participate in drug metabolism and that cardiovascular CYPs are 
responsible for the clearance of drugs from the heart (Michaud et al., 2010). Since 
CYP2J2 is expressed in the human lung and is the most abundant P450 expressed in the 
human heart (Wu et al., 1996; Zeldin et al., 1996), it is important to investigate the ability 
of members of the CYP2J family to catalyze the metabolism of the SC of abuse, JWH-
018. 
In the reconstituted system, recombinant CYP2J2 metabolized JWH-018 
primarily to give the ω-1-OH metabolite with the concomitant formation of a small 




two metabolites as CYP2J2, but the metabolite profile was extremely different. The ratios 
of ω-OH to ω-1-OH for CYP2C9 and CYP2J2 were 2.5:1 and 1:5, respectively. Although 
the kcat values for the formation of the ω-1-OH metabolite of JWH-018 were the same for 
the CYP2J2 and CYP2C9 catalyzed reactions, CYP2C9 was approximately five times 
more efficient than CYP2J2 at catalyzing the formation of the ω-1-OH JWH-018 
metabolite and 83 times more efficient at forming the ω-OH JWH-018 metabolite based 
on the kcat/KM values. When discussing purified protein, the order of efficiency goes from 
CYP1A2 > CYP2C9 > CYP2C19 > CYP2J2 > CYP2D6. Interestingly, we found that the 
addition of JWH-018, rather than acting as a competitive inhibitor, significantly increased 
the CYP2J2-catalyzed metabolism of AA, its endogenous substrate, leading to the 
formation of all four EETs, especially at equimolar ratios. Although the ratios of JWH-
018 to AA will probably never reach equimolar ratios in vivo, a ratio of 0.5 to 1 still 
significantly increased the formation of 8,9-, 11,12-, and 14,15-EETs. It is unlikely that 
an increase in EET formation during exposure to JWH-018 will cause an increase in 
blood pressure, but a decrease in circulatory resistance caused by EET-induced 
vasodilation might possibly trigger baroreceptor activation.  
Administration of JWH-018 to rats had little to no effect on HR; however, it did 
cause a significant increase in MAP compared to the vehicle control. Because the CB1R 
antagonist AM251 partially blocked the increase in blood pressure elicited by JWH-018 
administration, these studies suggest the involvement of the CB1 receptor in altering the 
MAP in response to JWH-018. Moreover, during the 30 min pretreatment with AM251 
there was a significant increase in HR and MAP when compared to the vehicle 




release resulting in a decrease in HR and MAP (Niederhoffer et al., 2003). This is in 
agreement with what we observed during pretreatment of the rats with AM251. However, 
our results also suggest that JWH-018 may cause some of the increase in MAP 
independent of CB1 receptor activation since pretreatment of the rats with AM251 only 
partially blocked the decrease in blood pressure. It is unlikely that JWH-018 is acting at 
the CB2 receptor because its activation is usually devoid of cardiovascular effects, but 
this area remains largely unexplored (Pacher and Mechoulam, 2011).  
Several reports describe an increase in blood pressure after smoking marijuana 
which can be attributed to centrally mediated effects of CB1 receptor activation (Rudz et 
al., 2012). This may explain the increase in MAP after JWH-018 administration since 
centrally mediated effects, which are opposite of the peripheral effects of cannabinoids, 
override the peripherally mediated effects (Rudz et al., 2012). Another possibility could 
be that JWH-018 or one of its metabolites act as antagonists at either PPARγ or PPARδ 
to increase blood pressure. It has been shown that agonists of either of these receptors can 
decrease blood pressure (Cheang et al., 2013; Walker et al., 1999; Zarzuelo et al., 2011). 
As such, it is important to understand the metabolism of JWH-018 in order to identify the 
compound responsible for the adverse cardiovascular effects. 
Several product peaks were observed at m/z 358 following metabolism by human 
and rat microsomes. The ω-OH and ω-1-OH JWH-018 metabolites were only observed in 
human intestine and liver microsomal samples; however, the ω-1-OH JWH-018 
metabolite was only observed from certain lots of HIM (data not shown). The HIM used 




used. Microsomal protein from Lot # 05886 formed the ω-1-OH metabolite, while the 
HIM from Lot # 3077535 did not (data not shown).  
The M4, M5, and M6 metabolites were observed in all samples following 
metabolism by human and rat microsomes, whereas the M7 metabolite was only seen in 
RHM preparations. The product peaks M5, M6, and M7 are likely to correspond to 6-, 5-, 
and 7-hydroxyindole metabolites of JWH-018, respectively, based on the elution times of 
the commercially available standards. A reference standard compound was not 
commercially available for the M4 metabolite. This product could either have a hydroxyl 
group on the carbon side chain at a position other than the ω or the ω-1 carbon or it could 
be on the naphthyl group (Figure 4.8). 
The possible carboxylic acid metabolite, which would be observed at m/z 372, 
could not be detected in any of the preparations. Two peaks (M12 and M14) were 
identified at m/z 374 in the human liver microsomal samples, but nine separate peaks 
with m/z values of 374 were observed in RLM preparations corresponding to M11-M19. 
Because no standards are available, these metabolites could not be positively identified. 
Based on their molecular weights and potential substitution sites, these metabolites are 
probably dihydroxylated metabolites containing two hydroxyl groups on the indole ring, 
the naphthalene group, and/or the carbon side chain (Figure 4.8) (Wintermeyer et al., 
2010; Zhang et al., 2006).  
The peaks present in the extracted ion chromatograms with m/z values of 376 
suggest the formation of dihydroxylated products originating from epoxides. 
Recombinant CYP2C9 formed M8 only, while the microsomes showed the formation of 




have been extracted from urine samples of subjects who smoked JWH-018 (Sobolevsky 
et al., 2010). Likewise, phase I metabolism studies of JWH-018 by HLM conducted by 
Wintermeyer and coworkers demonstrated the formation of these two metabolites 
(Wintermeyer et al., 2010). Moreover, the metabolism of two other SCs, JWH-015 and 
WIN55212-2, showed the formation of only two reduced 1,2-diols even though there are 
four possibilities for the dihydroxylation of the naphthyl ring (Zhang et al., 2006; Zhang 
et al., 2002). These diols were then further hydroxylated to give several other metabolites 
which could be observed at m/z 392 (Wintermeyer et al., 2010). The ability of these 
products to form in vivo is likely since M20-M28 were formed in the HIM and/or the 
RLM. Likewise, the M3 metabolite isolated from RHM that was observed at m/z 338, 
probably originated from a 1,2-diol that lost its carbon side chain in a rearrangement and 
was subsequently dihydroxylated on the indole ring and/or the naphthalene group (Figure 
4.8).  
In conclusion, JWH-018 was metabolized by CYP2J2 to two metabolites that 
were hydroxylated on the side chain with the ω-1-hydroxylated compound as the major 
metabolite. In human intestine and liver microsomes, all products observed at m/z values 
of 358 and 376 were formed in large quantities and could be considered major products 
as opposed to the minor products observed at m/z 374 and 392 for the liver and intestinal 
microsomes, respectively. For incubations with RHM, the metabolites observed at m/z 
358 and 338 were formed in the highest amounts while the diol products at m/z 376 were 
formed to lesser extinct. However, in RLM the 1,2-diols (m/z 376) were a major product 
along with the mono-oxygenated metabolites observed at m/z 358. Although there was 




relatively less than the products observed at m/z 358 and 376. Because the rats 
experienced some of the same cardiovascular side effects as humans, these effects may be 
caused by the same compounds. It is possible that JWH-018 is responsible for these 
effects but major metabolites formed by RLM and HLM including the diols observed at 
m/z 376 in addition to M4, M5, and M6 can potentially be responsible as well. The 
potential targets and activities of the most of the mono-oxygenated products have been 
previously studied (Brents et al., 2011; Chimalakonda et al., 2012), but the receptor 
targets and the effects of the 1,2-diols (m/z 376), the other major metabolites, have not. It 
is important to determine whether these diols and their secondary metabolites (e.g. 
compounds with m/z values at 338 and 392) bind to the cannabinoid receptors or another 
receptor family with an appreciable affinity and efficacy. It is possible that the adverse 
effects associated with the use of SCs are mediated by the parent, one or more 
metabolites, or a synergistic interaction between the metabolites and the parent 
compound. Combining two or more SCs has been reported to result in synergistic effects 
(Brents et al., 2013). Moreover, although the one biologically active metabolite of ∆
9
-
THC exhibits less affinity for the CB1R (Kochanowski and Kala, 2005), this is not the 
case for synthetic cannabinoid metabolites which can contribute to the effects of the 
parent synthetic compounds (Brents et al., 2011; Chimalakonda et al., 2012; Rajasekaran 
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Conclusions and Future Directions 
Cytochrome P450 2J2 (CYP2J2) is believed to be the P450 most responsible for 
the metabolism of AA and other polyunsaturated fatty acids (Arnold et al., 2010; Moran 
et al., 2000; Wu et al., 1996). The highest expression levels of CYP2J2 are in the 
cardiovascular system, but it is also found at lower levels in other tissues including the 
liver, gastrointestinal tract, monocytes, macrophages, and brain (Bystrom et al., 2011; 
Chen et al., 2011; Jiang et al., 2005; Wu et al., 1996; Zeldin et al., 1997; Zeldin et al., 
1996)). Interestingly, all of these tissues also express some or all of the components of 
the endocannabinoid system (ECS) (Han et al., 2009; Pacher et al., 2006; Wright et al., 
2008). In order to try to investigate the possible functional relevance of the colocalization 
of CYP2J2 and the ECS, AEA, an endogenous cannabinoid, and JWH-018, a synthetic 
cannabinoid, were investigated as possible substrates for CYP2J2. 
The data presented in Chapter II characterized the metabolism of AEA by 
CYP2J2. When incorporated into the standard reconstituted system, recombinant CYP2J2 
metabolizes AEA to produce 20-HETE-EA and 5,6-, 8,9-, 11,12-, and 14,15-EET-EAs. 
Data on the metabolism of AEA by human intestinal microsomes (HIM) were also 
presented. The metabolites formed during the metabolism of AEA by HIM were the same 
as those formed by CYP2J2 in the reconstituted system with the additional formation of 




previously been suggested by reports of its contribution to the intestinal metabolism of 
certain drugs (Hashizume et al., 2002; Matsumoto et al., 2002). However, our studies 
reported in Chapter II suggest that CYP2J2 does not contribute significantly to the 
intestinal metabolism of AEA. However, in Chapter IV we reported that different lots of 
commercially available HIM exhibited different product profiles for the metabolism of 
JWH-018. As a result, the lack of significant involvement of CYP2J2 in intestinal AEA 
metabolism reported here may not be entirely true and needs to be investigated further 
with additional lots of HIM. 
Our lab has previously studied the metabolism of AEA by human kidney and liver 
microsomes, HKM and HLM, respectively (Snider et al., 2007). HKM incubated with 
AEA only yield the 20-HETE-EA, whereas HLM and HIM incubations with AEA 
produce 19- and 20-HETE-EAs (Snider et al., 2007). Liver microsomes are 2 and 44 
times more efficient at catalyzing the formation of 20-HETE-EA than kidney and 
intestine microsomes, respectively, based on Vmax/Km values. HLM produced all four 
EET-EAs in the presence of AEA, but HIM failed to produce the 14,15-EET-EA, 
although the other three epoxides were formed. The absence of 14,15-EET-EA formation 
in HIM is reversed by the addition of an epoxide hydrolase inhibitor to reaction mixtures. 
Liver microsomes were several orders of a magnitude more efficient at catalyzing the 
formation of 5,6-, 8,9-, and 11,12-EET-EAs when compared to HIM (Snider et al., 2007). 
In HLM, the 8,9-EET-EA metabolite is the major epoxide formed in respect to quantity 
and efficiency, but this is not the case for HIM (Snider et al., 2007). The 5,6-EET-EA 
metabolite was the major product formed from AEA by HIM based on quantity and 




nanomolar range (Snider et al., 2009). As such, there may be some potential 
physiological relevance for this metabolite in the human gastrointestinal (GI) tract. 
Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of 
all or part of the digestive tract. Crohn’s disease is an IBD typically confined to the lower 
end of the small intestine (Di Carlo and Izzo, 2003). Patients suffer intestinal cramps and 
spasms, severe diarrhea, rectal bleeding, nausea and vomiting, and loss of appetite and 
weight that can lead to malnutrition (Britton and Peppercorn, 1997). Some reports 
indicate that people suffering from Crohn’s disease get symptomatic relief by smoking 
marijuana (Di Carlo and Izzo, 2003). This effect has been attributed to the ability of 
marijuana to stimulate appetite, alleviate nausea, control spasms, and potentially reduce 
inflammation (Grinspoon and Bakalar, 1997; Nocerino et al., 2000). Some of these 
salutatory effects may result from activation of the CB2 receptor by ∆
9
-THC. If this is 
true, there may be a pathophysiological relevance for the 5,6-EET-EA in the inflamed 
gut. 
All of the components of the ECS have been detected in the GI system (Wright et 
al., 2008). The CB1 receptor is colocalized with choline acetyltransferase in neurons and 
nerve fibers of the stomach, small intestine, and colon (Kulkarni-Narla and Brown, 2000, 
2001). As a result,  activation of presynaptic CB1 receptors in myenteric nerves and the 
submucosal plexus neurons decreases intestinal motility as well as the secretion of gastric 
acid and intestinal fluids (Di Carlo and Izzo, 2003; Mascolo et al., 2002; Pinto et al., 
2002; Wilson and Nicoll, 2002).  It is widely known that CB2 receptors are expressed on 




2005; Klein, 2005; Lunn et al., 2006). However, the physiological function of the CB2 
receptor in the gut has not been well studied. 
In inflammatory disorders the ECS becomes overstimulated in the small and large 
intestine (Di Marzo and Izzo, 2006). Evidence suggests that the levels of 
endocannabinoids (ECBs) and CB1 receptors are significantly increased during intestinal 
inflammation (D'Argenio et al., 2006; Izzo et al., 2001). It is believed that the ECBs 
activate the CB1 receptors to protect against both the epithelial damage and the increased 
motility observed with intestinal inflammation (Izzo et al., 2003; Massa et al., 2004). 
However, although intestinal motility is attributed to CB1 receptor activation, in an 
inflammatory state the CB2 receptor may predominate. In a rat model where the animals 
are exposed to lipopolysaccharide (LPS) to stimulate inflammation and cause an increase 
in GI transit, activation of the CB2 receptor exhibited a dose-dependent inhibition of the 
LPS-induced increase in GI transit to control levels; however, the  control of basal GI 
activity was attributed the to the CB1 receptor activity (Mathison et al., 2004). Moreover, 
activation of the CB2 receptor has been shown to inhibit the release of inflammatory 
mediators that are known to encourage intestinal peristalsis (Izzo, 2004; Mathison et al., 
2004). The activation of CB2 receptors expressed on human colonic epithelial cells has 
been found to inhibit the TNF-α-induced release of the inflammatory cytokine 
interleukin-8 (Ihenetu et al., 2003). Because we identified 5,6-EET-EA as the major AEA 
metabolite formed in intestinal microsomes and it can activate the CB2 receptor at 
nanomolar concentrations, these observations may indicate a physiological function for 





Data were also presented in Chapter II describing the effect of obesity and a junk 
food diet on the ability of rat liver microsomes (RLM) to metabolize AEA. Somewhat 
surprisingly, the RLM did not produce any of the traditional metabolites such as the EET-
EAs and HETE-EAs observed in studies of human liver metabolism. However, we were 
able to identify and monitor the formation of three new metabolites to observe for any 
influence of obesity and diet on AEA metabolism. Because the identity of these products 
is unknown, we were unable to quantify the amount of the products formed. To 
compensate, we used the peak area ratio (unknown metabolite peak area/internal standard 
peak area) to determine relative amounts of formation. The formation of the two products 
observed at m/z 356 was dramatically increased in the microsomes of livers from obese 
rats as compared to lean controls fed a normal diet. The junk food diet seemed to have no 
effect on the formation of these metabolites, but this conclusion will need to be 
confirmed using liver microsomes prepared from diet-induced obese rats on a junk food 
diet. On the other hand, the formation of the product monitored at m/z 380 was 
significantly decreased as a result of obesity and even more so as a result of the junk food 
diet. Completing studies to investigate AEA metabolism by liver microsomes prepared 
from diet-induced obese rats fed a junk food diet are needed to validate this conclusion. 
Identification of these products observed at m/z 356 and 380 and their biological actions 
would be the most important step to determine the physiological relevance of altered 
AEA metabolism in response to diet and obesity. 
Due to the opposing patterns of formation for the products observed at m/z 356 
with regard to the product observed at m/z 380, it will be of interest to determine the 




interactions with the CB1 and CB2 receptors in order to fully understand the possible 
physiological relevance of these data. If the compounds observed at m/z 356 contain 
terminal hydroxyl groups and the metabolite at m/z 380 contains an epoxide, it would 
strongly suggest that junk food diets and obesity increase inflammation by a mechanism 
involving the ECS because terminally hydroxylated fatty acids are believed to be 
proinflammatory and epoxygenated fatty acids are considered to be anti-inflammatory 
(Imig, 2012; Morisseau and Hammock, 2013; Spector, 2009; Williams et al., 2010).  
Thus, it would be necessary to complete similar metabolism studies using some of the 
essential ω-3 and ω-6 fatty acids such as EPA or AA especially because of their potential 
involvement in obesity-related inflammation (Kim et al., 2013; Tilley et al., 2001). 
The studies conducted in Chapter III investigated AEA metabolism by human 
liver S9 fractions. The liver S9 fractions formed the same metabolites as those previously 
reported to be produced by human liver microsomes (Snider et al., 2007). Because 
soluble epoxide hydrolase inhibitors (sEHIs) have proven to be extremely beneficial in 
determining the biological activities of the EETs in vivo, the potent sEHIs AUDA, 
APAU, and TPPU were tested for their ability to inhibit the hydrolysis of the EET-EAs 
by soluble epoxide hydrolases in the S9 preparations. AUDA inhibited the hydrolysis of 
14,15-EET-EA with an EC50 value of 5.6 µM. At nanomolar concentrations, AUDA 
increased the levels of 11,12-EET-EA, but at concentrations of 10 µM or higher, AUDA 
decreased the levels of 5,6-, 8,9-, and 11,12-EET-EA in a dose-dependent manner. APAU 
increased the levels of all of the EET-EAs; however, only 11,12- and 14,15-EET-EAs 
exhibited a sigmoidal trend with respect to metabolite levels vs. concentration and their 




in the levels of 8,9-, 11,12-, and 14,15-EET-EAs induced by TPPU only occurred 
sporadically, as a result, the EC50 values could not be calculated for this sEHI. Our results 
suggest that it may be necessary to design sEHIs specific for the EET-EAs, since none of 
the three sEHIs investigated were able to inhibit sEH-mediated hydrolysis of the four 
EET-EAs equally. Using siRNA to knockdown sEH and mEH activity in hepatocytes in 
the presence of AEA would be a more efficient approach and would allow for 
observation of the biological actions of EET-EAs in a closed cell system. It is possible 
that this approach may be useful in vivo, but several other epoxides are likely to be 
effected as well making the results difficult to interpret. The development of sEHIs to 
increase the half-life of the EET-EAs will be extremely useful for determining their 
biological actions.  
The work described in Chapter IV demonstrated that purified human CYP2J2 
metabolizes the synthetic cannabinoid JWH-018 primarily to give the ω-1-OH JWH-018 
metabolite. Human intestine and liver microsomes were also investigated for their ability 
to metabolize JWH-018. The products formed by these systems included mono- and di-
oxygenated metabolites as well as two 1,2-diol products. It was determined that 
recombinant CYP2C9 catalyzed the formation of one of the diol products. The same 
products as well as several more were observed following metabolism by rat heart and 
liver microsomes. A total of 24 different metabolites were shown to be formed as a result 
of NADPH-dependent metabolism of JWH-018; however, most of those metabolites 
were observed in rat microsomes and are not applicable to human metabolism. Additional 
studies will be required to identify the major hydroxydiol metabolites and determine their 




their potential relevance as products of this commonly abused substance with a wide 
array of adverse side effects. If the mechanisms behind these side effects can be 
elucidated, perhaps treatments to reverse the effects can be developed as well. 
Studies on the effects of JWH-018 in vivo indicated that although it did not have 
much of an effect on heart rate, it significantly increased blood pressure in rats. This 
increase in blood pressure was only partially blocked by pretreatment with the CB1 
receptor antagonist AM251. This was not surprising since centrally mediated effects of 
cannabinoids have previously been shown to dominate over peripheral effects (Rudz et 
al., 2012). Centrally administered cannabinoids cause an increase in blood pressure, but a 
decrease in heart rate (Niederhoffer and Szabo, 1999). Because JWH-018 binds to both 
CB1 and CB2 receptors (Aung et al., 2000), it is possible that the lack of effect on heart 
rate may have something to do with the CB2 receptor activation or the activation of a 
non-cannabinoid receptor. Future studies focused on the cardiovascular effects of JWH-
018 using a CB2 receptor antagonist may provide information as to the biological 
relevance of CB2 receptor expression in the cardiovascular system. In addition, a non-
selective cannabinoid receptor antagonist will be of interest to investigate the possible 
involvement of another receptor unrelated to the ECS. 
In conclusion, CYP2J2 catalyzes the metabolism of the endogenous cannabinoid 
AEA and the synthetic cannabinoid JWH-018 to give a variety of hydroxylated and 
epoxygenated products. It is known that cannabinoids, especially CB2 receptor agonists, 
can inhibit inflammation (Hanus et al., 1999). Studies investigating the effect of JWH-
018 on the metabolism of AA revealed that JWH-018 actually increased CYP2J2-




interaction between cannabinoid-based substrates of CYP2J2 and AA have similar effects 
as JWH-018, this may suggest an alternative mechanism for the anti-inflammatory 
actions of the ECS, especially since inhibition of CYP2J2 activates inflammatory 
responses in vivo (Deng et al., 2011). Due to the overlap in the expression and functions 
of CYP2J2 and the ECS, in conjunction with the ability of CYP2J2 to metabolize 
cannabinoids, there is a potential for CYP2J2 to play a critical role in the metabolic fates 
of some endogenous ligands of the CB1 and CB2 receptors and thereby modulate the 
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